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ABSTRACT

PROTO-ONCOGENE REGULATION BY GROWTH FACTORS
IN BONE CELLS
By
Harold L. Merriman

Previous studies have shown that bone cells in culture produce a number of
growth factors that are important in bone regulation. Chick and mouse primary
calvarial cultures consist of a mixture of cell types that make it difficult to interpret
the results from these model systems. In contrast, MC3T3-E1 cells are a clonal
mouse osteoblast-like cell line. Since MC3T3-E1 cells consist of a single popula
tion of calvarial cells, they make an ideal system in which to study the autocrine
effects of bone growth factors.
Based on this work, MC3T3-E1 cells are now known to produce IGF-I,
TGF-beta and IGF-II in descending order of abundance. These growth factors also
act on MC3T3-E1 cells in an autocrine manner. IGF-I and IGF-II increase while
TGF-beta decreases cell proliferation as measured by ^H thymidine incorporation.
MC3T3-E1 cells also produce two IGF binding proteins-MC-IGFBP-1 and MCIGFBP-2. The major BP, MC-IGFBP-1, has N-terminal sequence identity with
CSF BP which is found in cerebrospinal fluid. The minor BP, MC-IGFBP-2, Nterminal has sequence identity with In-IGFBP which is found in human bone cell
conditioned medium. This is the first time that 1) an IGF BP (MC-IGFBP-1) with
selective affinity for IGF-II has been shown to be produced by bone cells, and 2) InIGFBP (MC-IGFBP-2) has been shown to be produced by non-human bone cells.
To determine how growth factors made by MC3T3-E1 cells might act on

these cells at the molecular level, the expression of several proto-oncogenes was
studied. IGF-I and IGF-II cause a rapid and transient induction of c-fos in MC3T3E1 cells similar to that observed with other growth factors in other cell types. TGFbeta causes a similar rapid induction of c-fos which is slightly delayed. IGF-I and
TGF-beta have no effect on the expression of c-jun and jun-D transcripts, while
IGF-II moderately induces these transcripts. In contrast, jun-B transcripts are
undetectable with IGF-I and IGF-II, but TGF-beta rapidly and dramatically
induces jun-B in MC3T3-E1 cells. Thus, the differences in the c-fos and jun-B
inductions may be a component in the molecular mechanism controlling cell
proliferation in the MC3T3-E1 cell autocrine system.
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I. INTRODUCTION

A,

BONE VOLUME REGULATION
Bone volume is controlled by two separate processes-bone formation and

bone resorption. It is well established that bone volume is regulated by systemic
agents that maintain blood calcium and phosphate concentrations. However, when
rats are treated with agents that stimulate bone resorption (calcium or phosphorus
deficiency), they show evidence of increased bone formation when calcium or
phosphorus is added back [Thompson et al, 1975]. Later studies showed that when
the systemic hormone PTH is administered to rats, osteoblast number and activity
increases in addition to the increase in bone resorption [Baylink & Liu, 1979].
Since systemic factors could not account for the increase in bone formation, the
hypothesis was proposed that the coupling of bone formation to bone resorption is
mediated locally. This coupling could then serve as a counter regulatory mecha
nism for the maintenance of bone volume.
B.

BONE GROWTH FACTORS AND LOCAL REGULATION
Studies in our lab to identify the factors involved in the local regulation of

bone volume have led to the identification of a bone growth factor called skeletal
growth factor. SGF is found in chicken, human and bovine bones and has prolifera
tive activity on chicken calvarial cells [Drivdahl et al., 1982; Farley & Baylink, 1982;
Jennings & Baylink, 1985]. SGF is also the most abundant growth factor in adult
human bone matrix [Mohan et al., 1988a], and recently has been found to be struc
turally identical with IGF-II [Mohan et al., 1988c].
In addition, other studies have shown that bone contains a number of addi
tional growth factors which include IGF-I, TGF-beta, acidic and basic FGF, PDGF,
bone morphogenetic proteins and hematopoietic factors [Mohan & Baylink, in
1
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press]. Therefore, bone can be viewed as a storehouse of proteins that potentially
may be involved in local regulation of bone volume. Evidence supporting this
concept includes studies which show that growth factors are stored in bone matrix
and that bone cells in culture produce many of these growth factors [Wergedal et
al., 1990; Kasperk et al., in press; Mohan et al., 1988a; Linkhart et al., 1986a].
These same growth factors are also known to have important biological effects on
bone cells. Thus, bone growth factors are likely to have physiological significance
in the local regulation of bone growth in vivo.
C.

MODELS OF LOCAL BONE REGULATION
There are several possible ways in which bone cells could be regulated local

ly by growth factors [Mohan & Baylink, 1990b]. In a paracrine model, growth
factors secreted by one cell type would then exert their biological effects on neigh
boring cells of a different type. For example in bone, an osteoblast might release a
growth factor that would act on a neighboring pre-osteoblast [Mohan et al., 1984;
Linkhart et al., 1984].
Another possible way that bone growth factors might act locally in bone
would be in a delayed paracrine manner. In this model, bone cells would secrete
growth factors that would then be stored in the bone matrix. When the bone was
resorbed by osteoclasts, these growth factors would then be released in a bioactive
form to act on neighboring cell types in a paracrine manner [Farley et al., 1987].
Finally, the third way in which growth factors could act is in an autocrine
manner. In this case, bone cells would secrete growth factors which in turn would
act on the same cells that secrete them to regulate their proliferation and/or activi
ty. An easily studied example of an autocrine model is a clonal osteoblastic cell
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line which secrete growth factors that can act on the same type of cells [Merriman
et al, 1986].
The rest of this section will briefly discuss the structure, action and regula
tion of bone growth factors pertinent to this work followed by a section on one
potential area of growth factor action--fos and jun proto-oncogenes.
D.

INSULIN-LIKE GROWTH FACTORS

I.

IGF Structure

a.

IGF-I
Human IGF-I is a basic 70 amino acid residue single chain polypeptide with

a molecular weight of 7,649 that is cross linked by three disulfide bonds [Rinderknecht & Humbel, 1976]. IGF-I is now known to be identical to somatomedin C, a
growth hormone dependent serum mitogen [Klapper et al., 1983]. IGF-I is synthe
sized as a pre-pro-polypeptide consisting of 131 amino acid residues. The final
form of IGF-I is produced by cleavage of the 25 amino acid pre-segment and the 36
amino acid C-terminal E domain. Human IGF-I has 62% identity with human
IGF-II and 40% with human insulin [Rinderknecht & Humbel, 1978a & 1978b].
The human IGF-I gene spans a region of at least 45 kb on chromosome 12.
Human and rat IGF-I genes contain at least 5 exons, each of which contain some
coding information in contrast to the IGF-II gene. Two different mRNAs can be
generated from the human gene by alternative processing of the primary transcript
[Rotwein et al., 1986]. cDNA IGF-I probes identify at least four different sizes of
transcripts from rat mRNA preparations [Roberts et al., 1986]. Thus, the expres
sion of both human and rat IGF-I genes is very complex and involves a number of
polyadenylation and alternative splicing sites.
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b.

IGF-II
Human IGF-II is a neutral 67 amino acid residue single chain polypeptide

with a molecular weight of 7470. IGF-II, like IGF-I, is cross linked by three disul
r-

fide bonds and is synthesized as a pre-pro-polypeptide which contains 180 amino
acid residues [Rinderknecht & Humbel, 1976 and 1978a]. The final form of IGF-II
is produced by cleavage of the 24 amino acid leader sequence and the 89 amino
acid C-terminal E domain [Bell et al., 1984a & 1984b; Dull et al., 1984]. Human
IGF-II shows 40% identity with human insulin [Rinderknecht & Humbel, 1978a].
The human single copy IGF-II gene is about 30 kb long, and is near the
insulin gene on chromosome 11 [Bell et al., 1985]. The IGF-II gene has multiple
promoters and exons though the exact number is unclear. The current understand
ing is that the human IGF-II gene consists of 4 promoters and 9 exons (5 non
coding) while the rat gene has 3 promoters and 6 exons (3 non coding) [Daughaday
& Rotwein, 1989; Sussenbach, 1989; Holthuizen et al., 1990]. It is also known that
human bone cells produce some transcripts that are unique [Strong et al., 1989].
Thus, IGF-II gene regulation, like IGF-I, is complex and involves alternative splic
ing and polyadenylation sites.
2.

Biological Actions of IGFs in Bone Cells
Both IGF-I and IGF-II stimulate cell proliferation in a dose dependent

manner in monolayer cultures of human bone cells, in primary mouse serum-free
cultures and in embryonic chick calvarial serum-free cultures [Wergedal et al.,
1990; Kasperk et al., in press; Mohan et al., 1989b; Linkhart et al., 1986a]. Other
studies show that IGF-I stimulates differentiation associated markers such as colla
gen and bone matrix synthesis in 21 day old fetal rat calvarial cultures [Canalis &
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Lian, 1988a; Hock et al., 1988; McCarthy et al, 1989b]. IGF-I also stimulates bone
formation in hypophysectomized rats in vivo [Schmid et al., 1989a; Zapf & Froesch,
1986]. IGF-II can stimulate type I procollagen mRNA in untransformed normal
human osteoblasts and collagen synthesis in rat calvarial cultures [Strong et al.,
1988; McCarthy et al, 1989b].
These findings for IGF-I and IGF-II show that both IGFs are involved in
bone cell proliferation and differentiation which are important for bone formation.
3.

Regulation of IGF Actions
Recent studies reveal that the actions of IGFs are regulated at a number of

levels which include a) IGF synthesis, b) IGF receptors, and c) IGF BPs. The
regulation at multiple levels would allow for the complexity needed for the tissuespecific actions of the IGFs. These three important aspects of IGF regulation are
described below.
a.

IGF synthesis
11 Cell types that produce IGFs: Historically, IGF-I was believed to be

synthesized primarily in the liver. IGF-I is now known to be produced in a large
variety of cell types. For example in rats, the highest concentrations of IGF-I are
found in kidney, lung and heart cells [Daughaday & Rotwein, 1989]. In contrast to
IGF-I, the tissue distribution of IGF-II in fetal and adult animals is not as well
known. One non-bone source of IGF-II is adult brain tissue, with the highest
concentrations being found in the anterior pituitary [Haselbacher et al, 1985].
In bones, IGF-II is found at concentrations 10-15 fold more than IGF-I in
human bone matrix and is produced 50-100 fold more by human bone cells [Mohan
et al, 1988a,b,c]. Newborn mouse bone extracts contain about 6-fold more IGF-II
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than IGF-I, while adult extracts contain about 3-fold more IGF-I than IGF-II
[Bautista et al., 1990]. In addition, organ cultures of newborn mouse calvaria re
lease several-fold more IGF-II than IGF-I [Linkhart et al., 1989]. In contrast to
human and mouse bone studies, rat CM from 21 day old fetal calvarial cultures and
rat monolayer cultures of parietal bone cells contain much more IGF-I than IGF-II
[Canalis et al., 1988c; McCarthy et al., 1989c].
2) Regulation of IGF synthesis: Previous studies have shown that IGF-I and
IGF-II production in osteoblasts can be regulated by systemic hormones. For
example, 17-beta estradiol stimulates the secretion of both IGF-I and IGF-II in
UMR 106 cells, which are an osteoblastic cell line derived from a rat osteosarcoma
[Gray et al., 1989]. PTH increases IGF-I production 5-10-fold and IGF-II produc
tion 2-fold in newborn mouse calvaria [Linkhart & Mohan, 1989]. In agreement
with these results, PTH increases IGF-I transcript levels 3-fold after 6 hr and IGF-I
protein levels 1.5-2-fold after 24 hr in monolayer cultures of rat osteoblasts [McCar
thy et al., 1989c]. Recent studies have shown that low amplitude frequency specific
electric fields can also increase IGF-II message level in human bone cells [Fitzsim
mons et al., 1990].
Taken together, these experiments suggest that IGF-I and IGF-II expression
is regulated at both the message and protein secretion levels,
b.

Receptors
The actions of IGF-I and IGF-II are known to be mediated by binding to cell

surface receptors. These receptors consist of two types (type I and type II) that are
expressed by a variety of tissues and cultured cells [Rechler & Nissley, 1985; Rosenfeld & Hintz, 1986]. The abundance and affinity of these receptors provide another
potential control point for IGF regulation.

*
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1) Type I: The complete cDNA and derived protein sequence are known for
the type I receptor [Ullrich et al., 1986]. This receptor, which is similar to the insu
lin receptor, has a heterotetrameric alpha2-beta2 subunit structure with a MW of
450,000 daltons. The alpha subunits contain the IGF binding sites, while the intra
cellular parts of the beta chains contain a tyrosine-specific protein kinase. This
kinase is activated by IGF-I binding and can autophosphorylate the receptor [Le
Bon et al., 1986]. The type I receptor has the highest affinity for IGF-I, but also
binds IGF-II and insulin with lower affinity [Redder & Nissley, 1985; Rosenfeld &
Hintz, 1986].
2) Type II: The complete cDNA and protein sequence are also known for
the type II receptor. In contrast to the type I receptor, the type II receptor consists
of a single polypeptide chain with a MW of 250,000 daltons and lacks intrinsic tyro
sine kinase activity [Morgan et al., 1987]. The type II receptor is now known to be
structurally homologous to the bovine cation independent mannose-6-phosphate
receptor [MacDonald et al., 1989]. It binds IGF-II with the highest affinity, binds
IGF-I with lower affinity but does not bind insulin [Rechler & Nissley, 1985; Rosen
feld & Hintz, 1986]. Thus, the type I receptor binds to IGF-I with the highest affini
ty, while the type II receptor binds to IGF-II with the highest affinity.
The role of type II receptors in mediating IGF-II actions on proliferation is
controversial. Anti-type I receptor antibodies can inhibit the actions of both IGF-I
and IGF-II in human fibroblasts and rat L6 myoblasts. This suggests that IGF-II
action is mediated by the type I receptor [Conover et al., 1986; Kiess et al., 1987].
However, anti-type II receptor antibodies inhibit the binding of IGF-II and inhibit
IGF-II mitogenic activity in mouse calvarial cells [Mohan et al., 1989a]. This

8

suggests that IGF-II action is mediated by type II receptors in bone cells.
3) Regulation of IGF receptors: IGF receptors may be a control point for
regulating IGF action. This could be accomplished by modulating either the recep
tor number and/or affinity. Evidence supporting this idea has been found in bone
cells. For example, insulin can upregulate the IGF-II receptor number in MG-63
human osteosarcoma cells, SaOS-2 human osteosarcoma cells, and embryonic chick
calvarial primary cultures without affecting receptor affinity for IGF-II [Fitzsim
mons et al., 1989]. These results suggest that at least the regulation of receptor
number plays an important role in IGF-II regulation.
So far two levels of IGF regulation have been discussed, the first involving
IGF expression and secretion and the second involving receptor regulation. The
third level of IGF regulation is by a class of proteins called binding proteins which
can specifically bind to the IGFs.
c.

IGF binding proteins
1) Structure: IGF activity has been known for many years to exist in human

serum at a molecular weight above 50 kDa. However, upon treatment with acid
this activity is present below 10 kDa [Buergi et al., 1966; Hall et al., 1975]. Zapf et
al. [1975] suggested that this phenomenon was due to IGF-I binding to a specific
carrier protein which appeared in the 50-150 kDa range on gel filtration chroma
tography. Later studies showed that two general types of IGF BPs exist in human
serum: 1) growth hormone dependent BPs (150 kDa) and 2) non-growth hormone
dependent BPs (30-40 kDa) [Baxter & Martin, 1989; Ooi & Herington, 1988].
Recent studies have shown that the original classification of IGF BPs into
two general types is inadequate as additional types of IGF BPs have been
discovered. The current method of classification assigns a number to a binding
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protein when it is cloned.
a) hIGFBP-1: This binding protein is perhaps better known by the following
names--BP-28 from amniotic fluid [Baxter et al., 1987], BP-25 from HEP G2 hepa
toma cells [Lee YL et ah, 1988], IBP-1 from the uterus [Brinkman et al., 1988a],
pregnancy-associated endometrial alphal globulin [Bell et al., 1988], and placental
protein 12 [Koistinen et al., 1986]. The hIGFBP-1 gene is a single copy gene that
spans 5,900 base pairs [Brinkman et al., 1988b]. IGFBP-1 has 234 amino acids with
a predicted MW of 25.3 kDa, which is smaller than the values (30-35 kDa) obtained
from SDS-PAGE. IGFBP-1 binds to IGF-I and IGF-II with similar affinity [Brinkman et al., 1988a; Lee YL et al., 1988].
b) hIGFBP-2: This binding protein is found in CM from rat liver BRL-3A
cells and Madin-Darby bovine kidney cells [Mottola et al., 1986; Szabo et al., 1988].
The gene encoding IGFBP-2 has been cloned from BRL-3A and human fetal liver
cDNA libraries [Binkhert et al., 1989; Brown et al., 1989]. The mature hIGFBP-2
has 239 amino acids with a predicted MW of 31.3 kDa. hIGFBP-2 has greater than
85% identity with the IGF BP from rat BRL-3 A cells, but less than 40% identity
with hIGFBP-1 and hIGFBP-3. hIGFBP-2 has a much higher affinity for IGF-II
than IGF-I [Brown et al., 1989; Mottola et al., 1986].
cl hIGFBP-3: This binding protein is better known as BP-53 or growth
hormone dependent binding protein and is the major IGF BP found in human
serum. hIGFBP-3 has a MW of approximately 150 kDa and consists of three
subunits: 1) a 85 kDa acid-labile subunit (alpha subunit), 2) a 53 kDa acid-stable
(beta subunit) and 3) IGF-I or IGF-II (gamma subunit). A beta and gamma
complex can form in the absence of the alpha subunit, but the formation of the
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alpha-beta complex requires either IGF-I of IGF-II [Baxter & Martin., 1989].
hIGFBP-3 has been cloned from an adult liver cDNA library [Wood et al., 1988].
The mature protein has 264 amino acids with a predicted MW of 28.7 kDa. The
difference from the observed MW of 43 kDa when run on SDS-PAGE and the
predicted MW is probably due to glycosylation. hIGFBP-3 does not have the RGD
sequence that is found in hIGFBP-1 and hIGFBP-2, which is found in many adhe
sive proteins present in the extracellular matrix [Ruoslahti & Pierschbacher, 1987].
Purified hIGFBP-3 binds IGF-I and IGF-II with equal affinity.
dl hIGFBP-4: This binding protein has been described as In-IGFBP and is
found in the CM of human osteosarcoma TE-85 and TE-89 cells, and human un
transformed bone cells and [Mohan et al., 1989c], The first 15 amino acids from
the N-terminus are: Asp-Glu-Ala-Ile-His-Cys-Pro-Pro-Cys-Ser-Glu-Glu-Lys-LeuAla. Based on this sequence information hIGFBP-4 was recently cloned from a
human osteosarcoma TE-89 cell library [La Tour et al., submitted]. Mature
hIGFBP-4, after removing the 21 amino acid leader sequence, has 237 amino acids
with a predicted MW of 25.9 kDa. This MW corresponds closely to the observed
MW of 25 kDa. The sequence of this binding protein is unique and has 35-38%
sequence identity with hIGFBP-1, 2, and 3. The 18 cysteine residues from each
IGF BP align identically. hIGFBP-4 binds to both IGF-I and IGF-II but not to
insulin.
e) Cerebrospinal fluid and fibroblast IGF BP: An IGF BP found in human
cerebrospinal fluid (CSF) [Roghani et al., 1989] and a similar BP secreted by the
A673 human rhabdomyosarcoma cell line have recently been isolated [Romanus et
al, 1989]. The first 15 N-terminal amino acid residues of the CSF BP are: Leu-AlaPro-Gly-(X)-Gly-Gln-Gly-Val-Gln-Ala-Gly-Ala-Pro-Gly. This sequence was
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reported to have some identity with hIGFBP-3 starting from residue 69, but based
on the N-terminal sequence the CSF BP appears to be unique. Under non
reducing SDS-PAGE, CSF BP has a MW of 34 kDa. CSF BP also has a 10-fold
higher affinity for IGF-II than IGF-I.
CM from a SV40-transformed human fibroblast cell line contains an IGF BP
that is similar to CSF BP [Martin et ah, 1990]. This BP does not cross react in RIAs
with either hIGFBP-1 or hIGFBP-3. The reported sequence of this IGF BP differs
only in the first amino acid of the 12 N-terminal amino acid residues. Fibroblast
BP begins with an arginine while the CSF BP begins with a leucine residue.
2) Biological actions of IGF BPs: The role of IGF BPs in regulating the
actions of IGFs is only beginning to be understood. The actions of hIGFBP-1
appear to vary depending on cell type, since hIGFBP-1 increases IGF-I stimulation
of cell proliferation in muscle cells [Elgin et ah, 1987], but inhibits IGF-I action at
high concentrations in cultured choriocarcinoma cells [Ritvos et ah, 1988].
hIGFBP-2 is one of the few BPs that binds to IGF-II with greater affinity than to
IGF-I. However, the action of purified hIGFBP-2 is unknown, but partially purified
hIGFBP-2 inhibits IGF binding and IGF-stimulated DNA synthesis in chick embryo
fibroblasts [Knauer et ah, 1980]. hIGFBP-3 can be stimulatory or inhibitory on
cells. For example in neonatal skin fibroblasts, hIGFBP-3 can inhibit or stimulate
cell proliferation depending on culture conditions [De Mellow & Baxter, 1988].
Purified hIGFBP-4 inhibits IGF-I and IGF-II activity in chicken calvarial cells and
serum stimulation in MC3T3-E1 cells [Mohan et ah, 1989c]. The action of CSF BP
is unknown. However, because CSF BP is found in cerebrospinal fluid, has a great
er affinity for IGF-II and brain is a very important non-bone source of IGF-II, this

12
binding protein may play an important role in regulating IGF-II levels in the brain
and in other parts of the nervous system.
3) Regulation of IGF BP production: Though the role of IGF BPs in regulat
ing IGF action is not well known, even less is known about how the IGF BPs
themselves are regulated. In addition, there are very few reports on the regulation
of IGF BP production in bone cells. However, estrogen and human growth hor
mone can increase the production of IGF BPs in primary cultures of rat calvarial
cells [Schmid et al., 1989b]. Studies in our lab have investigated the regulation of
hIGFBP-4. Forskolin, which stimulates cAMP production by activating adenylate
cyclase, increases the synthesis of hIGFBP-4 in a dose-dependent manner in TE-85
human osteosarcoma cell CM [Mohan et al., 1989c]. The effect of forskolin on InIGFBP production is probably mediated by cAMP, since dibutyryl cAMP as well as
other agents which increase cAMP (PGE2, IB MX) also increase production of InIGFBP. In addition, dibutyryl cAMP also decreases cell proliferation in TE-85 cells,
which suggests that hIGFBP-4 might have a direct role in decreasing TE-85 cell
proliferation [Mohan, 1990d]. Studies at the message level show that dibutyryl
cAMP increases hIGFBP-4 message levels in both TE-85 and in untransformed
human bone cells [La Tour, submitted]. These findings suggest that hIGFBP-4 is
regulated in bone cells.
As can be seen from these studies IGF BPs play a very important role in the
regulation of the IGFs, even though that role is not understood very well. The
various IGF BPs are produced by a variety of cells types, which suggests that the
actions of the IGFs are modulated in different cell types at the local level by the
presence of IGF BPs. Since the IGF BPs are also regulated locally, these proteins
could function throughout the body to provide tissue specificity for IGF actions.
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E.

TGF-BETA

1.

Structure
TGF-beta belongs to a family of proteins that share significant structural

similarity which include inhibin, activin and Muellerian inhibiting substance [Lyons
& Moses, 1990]. TGF-beta is synthesized as a 390 amino acid pre-pro-polypeptide.
Mature TGF-beta is produced by cleavage of the 29 amino acid pre-segment fol
lowed by cleavage of the pro-segment to yield a 112 amino acid segment. The
biologically active form of TGF-beta is a dimeric polypeptide (25 kDa) comprised
of two 112 amino acid subunits linked by disulfide bonds.
The TGF-beta family includes four different types of TGF-beta. The TGFbeta produced by human platelets is called TGF-betal [Assoian et al., 1983]. The
bovine cartilage-inducing factor A (CIF-A) is identical to TGF-betal [Seyedin et
al., 1986a]. TGF-beta is identical in all known species except for a single amino
acid substitution in murine TGF-betal [Derynck et al., 1986]. Another cartilageinducing factor called CIF-B is known as TGF-beta2. TGF-betal and TGF-beta2
have 71% sequence identity [Seyedin et al., 1986b]. Another member of the TGFbeta family is known as TGF-beta3. TGF-beta3 has been cloned from the human
A673 rhabdomyosarcoma cell line and has 80% sequence identity with TGF-betal
and 2 at the 112 amino acid C-terminus [Duke et al., 1988]. Finally, TGF-beta4 has
been cloned from a chicken chondrocyte library and shows 82, 64 and 71% identity
with the amino acid sequences of TGF-betal, 2 and 3, respectively [Jakowlew et al.,
1988].
2.

TGF-beta Biological Actions

14
TGF-betal has been extensively studied in a variety of bone systems where it
produces tissue and species specific actions. One important action of TGF-betal is
to inhibit cell proliferation. Inhibition is observed with fetal rat calvarial cells at
low density [Centrella et al., 1987], MC3T3-E1 cells [Noda & Rodan, 1986] and rat
osteosarcoma cells [Pfeilschifter et al., 1987a]. TGF-betal can stimulate cell pro
liferation in embryonic chick calvarial cells [Jennings et al., 1988], in newborn
mouse calvarial cells [Kasperk et al., in press] and in the human osteosarcoma
(Htb96) cell line [Datta et al., 1989].
TGF-betal can inhibit the formation of bone differentiation markers like
alkaline phosphatase in MC3T3-E1 cells [Noda & Rodan, et al., 1986] and collagen
production in articular chondrocytes [Skantze et al., 1985]. In other osteoblast
systems TGF-betal increases differentiation markers. These systems include colla
gen synthesis at both the message and protein levels in untransformed normal
human bone cells [Strong et al., 1988, submitted], collagen message in rat calvarial
cells [Centrella et al., 1987] and in rat osteosarcoma cells [Pfeilschifter et al.,
1987a]. TGF-betal also appears to be able to stimulate bone formation in vivo
[Joyce et al., 1989; Noda & Camilliere, 1989]. Interestingly, PTH, 1,25-dihydroxy
vitamin D3 and interleukin 1 stimulate release of TGF-betal [Pfeilschifter &
Mundy, 1987b].
The biological action of other members of the TGF-beta family have not
been nearly as well studied as those of TGF-betal. This is probably due to the
similar biological actions observed in other systems [Lyons & Moses, 1990]. TGFbetal does stimulate cell proliferation in embryonic chick calvarial cells and is
more potent than TGF-betal in this system [Jennings et al., 1988]. TGF-beta4 has
not been purified, therefore its biological action is unknown. These findings
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suggest that the biological actions of the TGF-beta family are complex and play a
critical role in the regulation of proliferation and differentiation in bone and other
tissues.
3.

Regulation of TGF-beta Actions

a.

TGF-beta synthesis
TGF-beta is synthesized by almost all cells, but is secreted by cells in culture,

and released by platelets in an inactive or latent form [Lawrence et al., 1984; Pircher et al., 1986]. Three different forms of latent TGF-betal have been reported. In
Chinese hamster ovary cells, the latent form consists of a 110 kDa complex made
up of the 25 kDa mature dimer plus an amino-terminal glycopeptide portion of the
TGF-beta precursor [Lyons & Moses, 1990]. Human platelet latent TGF-beta
consists of mature TGF-beta, the remainder of the precursor (74 kDa) and an
unidentified 135 kDa glycoprotein [Wakefield et al., 1988]. Latent TGF-beta is
also found in human serum complexed with alpha 2 macroglobulin [O’ConnorMcCourt & Wakefield, 1987]. Latent TGF-beta does not bind to TGF-beta recep
tors and is therefore not biologically active. Thus, activation of latent TGF-beta is
probably important in the regulation of TGF-beta.
The regulation of TGF-beta expression must be very important so that cells
can maintain the appropriate growth control, especially since the actions of TGFbeta are so diverse. In general, TGF-beta expression appears to be tissue specific.
The expression of the various TGF-beta members also varies across cell lines and
cell types [Derynck et al., 1988]. Little is known about the regulation of TGF-beta
in bone, though the activation of the latent form, like in other cell types, is apt to be
a key regulatory step. Experimentally, the latent form can be activated by acid,
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though activation may involve plasmin, a serine protease [Sato & Rifkin, 1989]
and/or deglycosylation in vivo [Miyazano et al., 1989].
b.

TGF-beta receptors
Three types of TGF-beta receptors have been identified all of which can

bind specifically to TGF-beta in the picomolar range [Massague et al., 1987]. Type
I TGF-beta receptors have a MW of 65 kDa and are found in a variety of mamma
lian cells [Cheifetz et al., 1986; Massague et al., 1987]. Type II receptors exhibit a
MW between 85 and 110 kDa in fetal rat osteoblasts and in chick fibroblasts
[Cheifetz et al., 1986]. Finally, type III receptors are glycoproteins which have a
ligand binding subunit with a MW of 280-330 kDa and are present in mammalian
fibroblasts and fetal rat bone cells [Massague et al., 1987]. In bone cells, several
different types of TGF-beta high affinity binding sites have been found. These
include fetal rat and ROS 17/2.8 and UMR-106 rat osteosarcoma cells [Centrella et
al., 1988; Robey et al., 1987]. How the different members of the TGF-beta family
interact with the various receptors needs to be determined. Interestingly, there
have been no reports indicating that TGF-beta receptors have kinase activity,
however, a GTP-binding protein may be involved in TGF-beta signal transduction
[Howe & Leof, 1989].
F.

OTHER BONE GROWTH FACTORS

1.

Fibroblast Growth Factor
FGF was originally found as an activity in extracts of pituitary and brain that

stimulated 3T3 cell growth [Gospodorowicz, 1974]. This activity is now known to
be due to two different proteins-acidic and basic FGF [Thomas et al., 1984; Esch
et al, 1985]. The major form of acidic FGF has 140 amino acid residues and a PI
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of 5.6. In comparison, the major basic FGF has 154 predicted amino acids, a MW
of 25 kDa and a PI of 9.6 [Moscatelli et al., 1987a]. Basic FGF has 55% sequence
identity to acidic FGF. Basic FGF is found in bovine and human bones at a 10-fold
higher concentration than acidic FGF and is also produced by osteoblasts [Mohan
& Baylink., in press; Hauschka et al., 1986].
FGFs can stimulate cell proliferation and differentiation, which are believed
to be mediated by high affinity cell surface receptors [Gospodorowicz et al., 1987;
Moscatelli, 1987a]. However, FGFs are not usually secreted, but bind to heparin
on the cell surface. Basic FGF stimulates cell proliferation in untransformed chick,
mouse, rat and bovine bone cells, but can inhibit DNA synthesis in rat osteosarco
ma cells [Mohan & Baylink, in press]. These findings suggest that FGFs are impor
tant regulators of bone cell metabolism.
2.

Platelet-derived Growth Factor
PDGF was first isolated from platelets as a factor that allowed fibroblasts to

grow in vitro. PDGF is now known to be able to stimulate cells of mesenchymal
origin which include osteoblasts [Ross et al., 1986; Kasperk et al., in press]. Platelet
PDGF consists of two polypeptide chains called A and B that form a 28-35 kDa
heterodimer. The two chains have 56% sequence identity. Independent regulation
of A and B chain gene expression allows the formation of three different dimers
(A-A and B-B homodimers and the A-B heterodimer), are expressed in different
cells [Hannink & Donoghue, 1989]. Human and bovine bone have PDGF-like
activity, while osteosarcoma cells lines produce PDGF in culture [Hauschka et al.,
1986; Mohan et al., 1988a]. The biological actions of PDGF include stimulation of
cell replication in embryonic chick calvaria and newborn mouse calvaria,
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stimulation of collagenous protein synthesis in rat calvaria and stimulation of bone
resorption in mouse calvaria via a prostaglandin mediated mechanism [Mohan &
Baylink, in press]. This suggests that PDGF is also important in the physiology of
bone regulation.
G.

POTENTIAL MOLECULAR MECHANISM OF GROWTH FACTOR
ACTION—FOS AND JUN

1.

Background of Oncogenes
Since the discovery of the first retroviral oncogene, v-src, and its cellular

homologue, c-src [Bishop, 1983], many other retroviral oncogenes (v-onc genes)
have been identified. In addition, activated proto-oncogenes have also been found
in human and animal tumor cells that can transform normal cells into cancer cells.
Proto-oncogenes (c-onc genes) are the cellular counterparts of v-onc genes that are
found in normal cells. Ways in which v-onc genes differ from c-onc genes include,
point mutations, rearrangements or insertional mutagenesis that may disrupt a
crucial regulatory region of a normal gene and/or add a powerful viral regulatory
element.
The protein products of proto-oncogenes can be characterized into three
general classes according to function: (1) growth factors and receptors; (2) media
tors of intracellular signal transduction pathways (proteins kinases and GTP-binding proteins) and (3) nuclear DNA-binding proteins. These three classes of proto
oncogenes are believed to interact in this manner. A growth factor (c-sis, PDGF)
binds to its receptor (c-erb-B, EGF receptor) and activates a cascade of intracellu
lar events of the signal transduction pathways (ras, G proteins; c-src, c-abl, tyrosine
kinases) leading to the regulation of gene expression by nuclear proteins (c-fos,

19
c-myc) which modulate transcription [Ransone & Verma, 1989].
This model of proto-oncogene action is especially relevant to bone cells,
since they produce various growth factors that have diverse effects. This diversity is
illustrated in bone cells which employ a variety of second messengers. For exam
ple, the type I receptor which has the highest affinity for IGF-I has intrinsic tyrosine
kinase activity. This would allow other proteins to be phosphorylated and a signal
to be carried from the cell surface to the cell interior. In contrast, the type II recep
tor which has the highest affinity for IGF-II lacks tyrosine kinase activity. Thus,
another type of second messenger must be employed to transduce a signal to the
cell nucleus. One possible second messenger is the phosphotidyl-inositol triphos
phate (PIP) pathway. The TGF-beta receptors, like the type II IGF receptors,
appear to lack kinase activity. However, it appears that a GTP-binding protein
might be involved in transducing the signal generated by TGF-beta [Howe & Leof,
1989]. Since proto-oncogenes are involved at all levels of transducing a signal from
the exterior to the interior of a cell, it is very likely that proto-oncogenes play an
important role in the regulation of bone growth.
2.

Fos Oncogene

a.

Structure of fos: The nuclear oncogene v-fos was first detected in the Finkel-

Biskis-Jinkins mouse osteosarcoma virus (FBJ-MSV) [Finkel et al., 1966; Finkel &
Biskis, 1968], followed by its detection in the Finkel-Biskis-Reilly mouse osteosar
coma virus (FBR-MSV) [Finkel et al, 1973]. The c-fos gene is approximately 3.5
kb in length, contains three introns and produces a mature transcript of 2.2 kb. The
half life of c-fos mRNA is 15-30 min [Lee WMF et al., 1988] while c-fos protein has
a half life of 2 hr [Mueller, 1985a].
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The viral fos protein encoded by FBJ-MSV is 381 amino acids long while the
normal c-fos protein has 380 amino acids and runs at 55 kDa on SDS-PAGE. The
apparent MW is different from the predicted MW of about 40 kDa presumably due
to a high content of proline and charged amino acids. The two proteins are identi
cal in the first 332 amino acids except for five single amino acid substitutions. The
remaining sequence in the C-terminal region of FBJ-MSV v-fos is different from cfos due to an out-of-frame deletion of 104 nucleotides. In contrast, the FBR-MSV
fos protein is quite different from the c-fos protein, mainly in that it is truncated at
both ends to give a protein of 236 amino acids [Mueller, 1985a]. Both viral and
cellular fos proteins can transform murine fibroblasts in vitro, but in order for the cfos protein to do this some of the 3’ non-coding AT-rich sequences must be re
moved from the c-fos gene [Verma & Graham, 1987].
Both v-fos and c-fos proteins are extensively post-translationally modified at
serine residues. The c-fos protein is even more modified at the C-terminal end
than the v-fos protein. Because of this extensive modification of the c-fos protein,
SDS-PAGE yields a smear of proteins from 55-65 kDa. Human and mouse c-fos
protein products show a high degree of sequence identity (94%) [Mueller, 1986].
b.

Expression of fos: The c-fos proto-oncogene shows a complex pattern of

expression. Some early development stage mouse tissues normally show high fos
levels. These include the amnion, yolk sac and the mid-gestation fetal liver [Muell
er et al., 1983 ; Mueller et al., 1984a]. Some human hematopoietic cells, differenti
ated neutrophils, blood monocytes and mature macrophages also show high c-fos
expression [Mueller, 1986].
In contrast, other cells and tissues normally show only very low c-fos expres
sion. In some of these cells though, c-fos expression is inducible. For example, the
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levels of c-fos are low in the rat brain, but increase markedly after seizures [Dragunow & Robertson, 1987]. In culture, FCS and the growth factors EGF, FGF and
PDGF that stimulate growth, induce c-fos in quiescent (serum-deprived) NIH-3T3
cells [Mueller et aL, 1985a]. This induction is rapid with c-fos mRNA levels in
creasing after a few minutes and reaching a maximum at 30 min (15-fold induction,
except EGF which is much less) and disappearing after 2 hr. IGF-I stimulates c-fos
transcript levels maximally (18-fold) at 30 min in rat L6 skeletal muscle cells [Ong
et al., 1987] and maximally at 20 min in rat FRTL5 thyroid cells [Damante et al.,
1988]. In contrast, TGF-beta induces a sustained expression of fos mRNA (still
detectable at 24 hr) in EL2 rat and mouse NIH 3T3 fibroblasts. Interestingly
though, only EL2 but not NIH 3T3 cells make detectable levels of fos protein
[Liboi et al., 1988].
In addition to the potential role of c-fos in cell growth, c-fos induction is also
associated with cell differentiation. For example, the human promyelocytic leuke
mia cell line HL60 can be induced to differentiate into macrophage-like cells by
TPA [Mueller et al., 1985b]. The kinetics of c-fos induction in HL60 cells is differ
ent from fibroblast cell kinetics in that maximum expression is observed at 30-45
min, but then decreases 3-5-fold for the next 48 hr. The differences between factorstimulated fibroblasts, and HL60 cells support the view that the c-fos gene product
can serve different functions in the cell.
Another well studied nuclear proto-oncogene is c-myc. Like c-fos, c-myc is
also inducible with a number of agents. In NIH-3T3 cells, message levels of c-myc
are maximally induced with FCS, EGF, FGF and PDGF at 1 hr, and then slowly
decrease to basal levels by 4 hr [Mueller et al., 1985a].
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c.

Regulation of fos expression: The c-fos promoter contains several sequence

elements like AP-1, SRE and CRE where various protein factors can bind to regu
late c-fos expression. Perhaps the most important of these elements is the AP-1 site
that allows the c-fos protein to bind to the c-fos promoter and negatively regulate
its own expression after serum stimulation [Sassone-Corsi et al., 1988b]. However,
if the C-terminal region of c-fos is replaced with a C-terminal region similar to one
found in v-fos, down-regulation of c-fos transcription is prevented [Wilson &
Treisman, 1988].
Another factor known to bind to the c-fos promoter is the serum response
factor (SRF). The SRF binds to the serum response element (SRE) which is re
quired for the serum-inducible transcriptional activation of the c-fos gene. The
SRE is also required for the induction of c-fos transcription by activators of protein
kinase C and other growth factors [Norman et al., 1988]. Induction of c-fos in NIH3T3 cells can also be caused by cAMP. This is mediated through a cAMP respon
sive element (CRE) which is distinct from the SRE [Fisch et al., 1988]. The c-fos
CRE may also be able to modulate the expression of upstream elements because
when it is inserted into a tissue-specific promoter, tissue-specific restriction of gene
expression is eliminated [Webster & Kedes, 1990].
3.

Jim Oncogene

a.

Structure of jun oncogenes: Recently, another nuclear proto-oncogene

product called c-jun, that has significant sequence identity with the yeast transcrip
tional activator protein GCN4, was found to be involved with gene expression [Vogt
et al., 1987]. Originally, it was identified as the transforming component of the
avian sarcoma virus 17 [Maki et al., 1987]. (The name jun comes from the
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Japanese ju-nana, which means number 17.) Normal avian and mammalian cells
carry c-jun genes which appear to lack introns [Hattori et al., 1988]. The c-jun gene
codes for two different sized transcripts--a major one 2.7 kb in length and a minor
one 3.2 kb in length. These two transcripts appear to be derived from multiple
polyadenylation sites. The c-jun message has a half life of 10-15 min [Ryseck et al,
1988].
The v-jun protein lacks 27 amino acids (near the N-terminus) found in the
334 amino acid long c-jun protein and also has a few other single amino acid substi
tutions [Lamph et al., 1988; Marx, 1988]. The c-jun protein has near complete
identity with the enhancer binding protein AP-1 and has a half life of at least 6 hr
[Bohmann et al., 1987; Angel et al., 1988]. In addition, c-jun protein has been
identified as the fos-associated protein p39, which in earlier literature had often
been found in c-fos protein preparations [Rauscher et al., 1988].
It is now known that the c-jun gene is a member of a larger family of genes.
The second member of the jun family, jun-B, was originally described by Ryder et
al. [1988a]. The 344 amino acid jun-B protein has one region near the N-terminus
that shows 59% sequence identity with the v-jun protein and another region at the
C-terminus that shows 65% sequence identity with the v-jun protein. The mouse
jun-B transcript is 2.1 kb.
Recently, a third member of the jun family, jun-D has been described [Ryder
et al., 1989]. The 341 amino acid jun-D protein is more closely related by sequence
to c-jun protein than to jun-B protein. jun-D protein, like jun-B protein, also has
two areas of sequence identity with the v-jun protein. The mouse jun-D gene codes
for a transcript 1.8 kb in length.
b.

jun-fos heterodimers and leucine zippers: All three jun family proteins have
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a leucine zipper region at the C-terminus and a basic DNA-binding domain on the
N-terminal side of the leucine zipper. The c-fos protein also has a leucine zipper at
the C-terminus [Landschulz et al., 1989]. In comparison, the myc protein contains
the leucine zipper region but lacks the basic DNA-binding domain [Dang et al.,
1989].
Leucine zippers are amphipathic alpha-helixes which are believed to be
orientated in parallel. The helixes contain four or five leucines at seven-residue
intervals [Landschulz et al., 1988]. The spacing of the leucines could allow them to
extrude from the helix and to dimerize by interdigitation with proteins that also
have leucine residues. Dimerization is believed to be mediated by hydrophobic
interactions between the leucine side chains. Evidence for dimerization includes
gel mobility and cross-linking studies [Nakabeppu et al., 1988].
The jun family of proteins bind to the promoter sequence TGACTCA which
has perfect dyad symmetry and is also known as the TPA-responsive promoter
element (TRE) or AP-1 site. This sequence was first found in the human metallothionein IIA promoter and is also present in other genes [Lee et al., 1987]. Each
palindromic half of this sequence is thought to interact with the DNA-binding
domain of one of the dimers [Vogt & Bos, 1989]. Though c-jun can form homodimers that bind to DNA, binding of c-jun is greatly enhanced when c-jun forms a
heterodimer with c-fos [Sassone-Corsi et al., 1988a]. In contrast to c-jun, c-fos
proteins do not form homodimers [Halazonetis et al., 1988].
c-jun protein can also form a heterodimer with the CRE-binding protein
(CREB) via a leucine zipper. The CREB binds to the CRE which has the sequence
TGACGTCA. This sequence differs from the AP-1 site by only an insertion of a
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single nucleotide. However, CREB does not dimerize with jun-B or c-fos proteins
[Benbrook & Jones, 1990]. In addition, recent studies indicate that the c-ets-1 and
c-ets-2 proteins cooperate with c-fos and c-jun proteins to activate transcription
[Wasylyk et al., 1990].
c.

Expression of jun oncogenes: c-jun, like c-fos, is inducible with a wide variety

of agents. For example, FCS induces c-jun expression in mouse NIH- 3T3 cells.
In this system c-jun transcripts increase dramatically after 30 min with a maximum
at 1 hr (30-fold), decrease slowly for the next 3 hr and then remain at that de
creased level for at least another 8 hr [Ryseck et al., 1988]. Unlike c-fos, low level
c-jun transcripts can be identified in uninduced NIH-3T3 cells [Lamph et al., 1988].
jun-B shows a similar pattern of expression in BALB/c 3T3 cells with transcripts
appearing within 15 min with a maximum accumulation at 1 hr and then decreasing.
However, in this system the increase of jun-B is greater than that of c-jun [Ryder &
Nathans, 1988b].
Compared to both c-jun and jun-B, jun-D mRNA is more abundant in non
growing BALB/c 3T3 cells and is stimulated less by serum. jun-D transcripts are
also more stable than the other jun transcripts [Ryder et al., 1989].
One recent study examined the effects of TGF-beta and c-jun and jun-B expression
on a number of different cell types [Pertovaara, et al., 1989]. TGF-beta was found
to increase c-jun and jun-B transcripts in human lung adenocarcinoma A549 cells
and in K562 human erythroleukemia cells. This increase was most visible at 4-5 hr
and then declined gradually to basal levels. However, in AKR-2B and NIH 3T3
cells, only jun-B was induced by TGF-beta. Thus, the expression of jun transcripts
is complex and may explain some of the pleiotropic effects of TGF-beta.
d.

Regulation of jun expression: In contrast to the negative autoregulation of
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the c-fos promoter by c-fos protein, the c-jun promoter contains an AP-1 site that
allows the c-jun protein to positively autoregulate its own expression. In addition to
an AP-1 site, the c-jun promoter also has one Spl and one CTF site [Angel et al,
1988].
Recent studies have shown that jun-B protein is a negative regulator of
promoters that contain a single TRE (or AP-1) site. Since the c-jun promoter
contains one TRE site, jun-B is able to negatively regulated c-jun. In contrast, junB protein is an efficient activator of constructs containing multiple TREs. Thus,
trans-activation by jun-B depends on cooperative interactions between adjacently
bound factors, while activation by c-jun does not [Chiu et al, 1989].
H.

STATEMENT OF THE PROBLEM
The purpose of this work is two fold. Firstly, I propose to determine if bone

cells produce growth factors which act in an autocrine manner. In this regard,
previous studies have shown that cultures of bone cells derived from human, mouse
and chick bone produce a number of growth factors including, IGF-I, IGF-II and
TGF-beta. Also, exogenous addition of purified growth factors to serum-free cul
tures of bone cells can increase cell proliferation and collagen synthesis [McCarthy
et al., 1989b]. Since these cultures contain a mixture of cell types including preosteoblasts, osteoblasts and fibroblasts, it is difficult to interpret 1) which cell types
are producing which growth factor or factors, and 2) whether a given factor stimu
lates both cell proliferation and collagen synthesis in one cell type or stimulates cell
proliferation in one cell type and collagen synthesis in another cell type. Thus,
although bone cells in culture can produce growth factors and respond to exoge
nous addition of those growth factors produced by bone cells, it is not clear whether
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one cell type (e.g. osteoblasts) produces growth factors which in turn act on the
same cell type in an autocrine manner. The use of a clonal cell line will help to
clarify this question.
Secondly, I propose to investigate the molecular mechanisms for growth
factor action. In this regard, I choose to investigate the effects of bone growth
factors on the expression of the nuclear proto-oncogene c-fos because it appears to
be associated with osteoblast proliferation: 1) c-fos is the transforming component
of the FBJ-murine osteosarcoma virus [Curran & Teich, 1982; Verma & Graham,
1987]. 2) When the c-fos gene is expressed at high levels in transgenic mice
[Ruether et al., 1987], multiple lesions of increased bone formation develop in the
mice with no visible effects on other tissues. 3) c-fos expression, determined by in
situ hybridization, is observed in the growth regions of fetal bone and mesodermal
web tissue, which are areas of active osteoblastic cell proliferation and differentia
tion [Mueller et al., 1982]. 4) Many cells rapidly and transiently express c-fos in
vitro in response to polypeptide growth factors which also can stimulate osteoblast
proliferation in vitro. [Mueller et al, 1984c; Greenberg & Ziff, 1984; Mohan et al.,
1984; Canalis et al., 1988b; Raisz, 1988].
During the course of my work on c-fos expression, it was discovered that the
fos protein binds to another oncogene product, called jun, which forms a hetero
dimer with the fos protein [Sassone-Corsi et al., 1988a]. Hence, I also investigated
the effect of bone growth factors on the expression of the three members of the jun
family (jun-B, c-jun, jun-D).
My studies proposed in this dissertation are based on the following two
general hypotheses. 1) The clonal osteoblast-like MC3T3-E1 cell line produces
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bone growth regulators that act in an autocrine manner to regulate MC3T3-E1 cell
proliferation. 2) Stimulation of cell proliferation by the IGFs and inhibition of cell
proliferation by TGF-beta in MC3T3-E1 cells are mediated by differential expres
sion of proto-oncogenes.
I.

MC3T3-E1 CELLS AS A MODEL SYSTEM
The selection of a model system is extremely important in that the results

will be interpreted based on this system. MC3T3-E1 cells were chosen for this work
since they are a clonal osteoblast-like cell line that have characteristics of differen
tiated osteoblasts [Kurihara et al., 1984]. Since MC3T3-E1 cells are a clonal cell
line, they consist of a single cell type in contrast to primary cultures which contain
several different cell types. This gives MC3T3-E1 cells an advantage for studies on
autocrine regulation, where factors secreted by a cell type act on that cell type. In
addition, experience had shown that MC3T3-E1 cells were easy to maintain in
culture and also responded to growth factors in a reproducible manner.
However, the disadvantage with this model system is that it is an established
cell line and may not behave identically to that of untransformed normal
osteoblasts in vivo. However, since it is difficult to obtain homogeneous cell
populations of osteoblasts in sufficient number, I have chosen MC3T3-E1 cells as a
model system.

II. MATERIALS AND METHODS

A.

MATERIALS

1.

Reagents
DMEM and trypsin were obtained from GIBCO (Grand Island, NY). Iron

supplemented bovine calf serum was acquired from Hyclone (Logan, UT). Petri
dishes, centrifuge tubes and cryovials were purchased from Corning Class Works
(Corning, NY). Multi-well plates were obtained from Costar (Cambridge, MA).
Recombinant human IGF-I was procured from CIBA-GEIGY (Basel, Switzerland).
IGF-II was isolated from human bones and its purity established by N-terminal
sequencing and amino acid composition analysis [Mohan et al., 1988c]. TGF-beta
was purchased from R&D Systems (Minneapolis, MN). Rabbit polyclonal antise
rum (UB286) was provided by the National Hormone and Pituitary Program
(kindly given by LE Underwood and JJ Van Wyk). Goat anti-rabbit and normal
rabbit serum were obtained from Pel-Freez (Rogers, AR). alpha-^^P-dCTP (3000
Ci/mmole) and

thymidine (50 Ci/mmole) were purchased from ICN (Irvine,

CA). Formaldehyde was from Baker (Phillipsburg, NJ). Absolute ethanol was
purchased from Aaper Alcohol and Chemical Co. (Louisville, KY). Methanol,
acetic acid, isopropanol, and chloroform were from Fisher Chemical (Fair Lawn,
NJ). Tris, glycine and Ecoscint A were obtained from National Diagnostics
(Highland Park, NJ). Acetonitrile was bought from Burdick and Jackson
(Muskegon, MI), while TFA was from Pierce (Rockford, IL). Precast gradient
polyacrylamide gels were acquired from Gel Tech (Hudson, OH). Guanidine
isothiocyanate was from Fluka (Ronkonkoma, NY). Cesium chloride was obtained
from Accurate Chemical (Westbury, NY). Nytran was acquired from Schleicher
and Schuell (Keene, NH), while Hybond was made by Amersham (Arlington
Heights, IL). Kodak X-OMAT AR x-ray film was used for autoradiography
29
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(Rochester, NY). Low melting point agar was purchased from FMC Corporation
(Rockland, ME). Bactotryptone, yeast extract and agar were from Difco (Detroit,
MI). Agarose, phenol, restriction enzymes, buffers and BSA for restriction digests
were purchased from USB (Cleveland, OH). Tetracycline and nuclease-and-protease-free BSA were from Calbiochem (La Jolla, CA). Formamide, lipofectin and
Opti-MEM I were acquired from BRL (Gaithersburg, MD). Other regents includ
ing geneticin, ampicillin and RNase-A were obtained from Sigma (St. Louis, MO).
2.

Solutions

Final concentration in parentheses
BP assay buffer: for 1 L--23.83 g Hepes (0.1 M), 1 g Triton X-100 (0.1%), 4.66 g
Na2C03 (44 mM), 0.2 g NaN3 (0.02%), pH 6.0 (final), then add 1 g BSA (0.1%),
store at 4°C
CsCl buffer: for 100 ml-95.97 g CsCl (5.7 M), 0.83 ml of 3 M sodium acetate pH 6,
use DEPC water, store at RT
Deionized formamide: melt at RT, for 50 ml-deionize with 5 g AG 501 x 8 resin,
stir for 30 min at RT, filter twice with Whatman #1 paper, aliquot and store at
-20°C
Denhart’s: for 500 ml of 50X stock-5 g of Ficoll (1%), BSA (1%) and polyvinyl
pyrrolidone (1%), use DEPC water, filter through disposable Nalgene filter
[Maniatis et al., 1982a], store at -20°C
DEPC water: for 1 L-100 ul DEPC to double-distilled water, let sit overnight,
autoclave, store at RT
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DMEM plus BSA: for 100 ml-0.1 g BSA (0.1%) in DMEM, store at 4°C
EDTA: for 500 ml--93.05 g disodium salt for 0.5 M, use DEPC water, pH 8.0
(final), store at RT
Ethidium bromide: 10 mg/ml, carcinogenic, store at -20°C
Formaldehyde: 37% (12.3 M), pH should be greater than 4.0, store at RT
Geneticin (G418): for 5 ml of 200X stock-about 800 ug G418 (80 ug/ul) (exact
amount will vary since G418 is about 50% pure) in 100 mM Hepes pH 7.3, add 5 ul
of G418 per ml of DMEM in plate, store at -20°C
GIT buffer: for 200 ml-94.53 g guanidine isothiocyanate (4 M final), 1.67 ml 3 M
sodium acetate pH 6, use DEPC water, These 2 reagents are good for 2 months at
RT. Add 0.36 ml of 2-mercaptoethanol (14.4 M) per 50 ml GIT buffer right before
use. The final solution is good for 2 weeks at RT.
Goat anti-rabbit antiserum: from frozen 1:1 stock make 1:15 final dilution in RIA
buffer
Hank’s buffer: for 2 L of 10X stock-160 g NaCl (1.37 M), 20 g glucose (55 mM), 8
g KC1 (54 mM), 1.20 g KH2PO4 (4.4 mM), 1.80 Na2HP04 (4.4 mM), 2.8 g CaCl2
(12.6 mM), 2.0 MgCl2 (4.9 mM), 2.0 g MgSC^ (4.1 mM), 2 ml phenol red, store at
4°C; when ready for 1 L dilute 10X to IX, pH 7.4 (final), 1 g of BSA
Luria broth (LB): bactotryptone (0.01%), yeast extract (0.05%), NaCl (0.01%),
autoclave, store at RT, add 100 ug/ml amp or 20 ug/ml tet when bacteria have
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antibiotic resistant plasmids
LB agar plates: add agar (1.5%) to Luria broth, autoclave, add appropriate antibi
otic (100 ug/ml amp or 20 ug/ml tet), pour into dishes, allow to cool at RT, store
upside down at 4°C
Lysozyme buffer: for 100 ml-glucose (50 mM), 2.5 ml of 1 M Tris-HCl (25 mM)
pH 8.0, 2 ml of 0.5 M EDTA (lOmM), autoclave, store at 4°C, add fresh lysozyme
(5 mg/ml) only to amount of buffer needed
Methylene blue stain: for 1 L--0.2 g of methylene blue (0.02%)40.8 g sodium ace
tate (0.3 M), pH 5.5 (final), store at RT in dark bottle, can reuse some solution
many times until dye fades
MOPS: for 1 L of 5X stock-41.86 g 3-(N-morpholino) propanesulfonic acid (200
mM), 6.81 g sodium acetate (50 mM), 1.861 g EDTA (5 mM), use DEPC water, pH
7.0 (final), autoclave (turns yellow), store at RT
Normal rabbit serum: from frozen 1:1 stock make 1:20 final dilution in RIA buffer
Northern loading buffer: for 1.5 ml-0.75 ml formamide (50%), 0.3 ml of 5X
MOPS (IX), 0.26 ml of 37% formaldehyde (6.4%), 0.1 ml of 80% glycerol (5.3%), 6
mg bromophenol blue (0.4%), 6 mg xylene cyanole (0.4%), 0.1 ml DEPC water,
store at -20°C
PBS: for 2 L of 10X stock-160 g NaCl (1.37 M), 22.3 g Na2HP04 (79 mM), 4 g
KC1 (27 mM), 4 g KH2PO4 (15 mM), pH 7.4 (final)
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Phenol/Chloroform/isoamylalcohol for DNA plasmid prep: remove phenol
(bottom layer) from water saturated phenol and put in graduated cylinder (fill half
way), add at least 1/3 volume of 1 M Tris pH 10.0, shake (in final container), pour
back into cylinder, repeat until the pH of the layer (aqueous) is at least pH 7.6 (best
at pH 8.0), remove the aqueous layer, add an equal amount of chloroform (will
remove some more water from phenol) and 1/49 volume of isoamylalcohol, add
some TE and shake, repeat TE step again, leave some TE as aqueous layer, place
at 4°C, phenol will become clear overnight, note that final ratio of phenol/chloroform/IAA is 49:49:2
Potassium acetate for plasmid prep: for 100 ml-60 ml of 5 M potassium acetate,
11.5 ml of glacial acetic acid, 28.5 ml of water, mix contents by inverting the tube
sharply several times, the final solution contains 3 M potassium and 5 M acetate
and has a pH of 4.8, store at RT
Rabbit polyclonal antiserum (1° Ab): from frozen 1:10 stock make 1:6000 final
dilution in RIA buffer
RIA buffer: for 1 L-200 mg Protamine S04, 4.14 g Na^PC^, 200 mg NaN3, 3.72
g EDTA, pH 7.5 (final), then add 2.5 g BSA RIA grade, store at 4°C
RRA binding medium: for 500 ml--500 ml DMEM, 2.3 g Hepes (20mM), pH 7.4
(final), 0.5 g BSA (1 mg/ml), store at 4°C
RRA lysis buffer: for 1 L-5 ml of 2M Tris-HCl (10 mM) pH 7.4, 19 g EDTA (5
mM), 20 ml of 10% SDS (0.2%), store at 4°C
SOC medium: for 100 ml--2 g bactotryptone (2%), 0.5 g yeast extract (0.5%), 1 ml
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of 1 M NaCl (10 mM), 0.25 ml of 1 M KC1 (2.5mM) are added to 97 ml distilled
water, autoclave, cool to RT, then add filter sterilized 1 ml of 2 M Mg + + (20 mM,
10 mM each made from 1 M MgC^-hl^O plus 1 M MgSC^-VI^O) and 1 ml of
2M Glucose (20 mM), pH 7.0 (final), store at RT
SSC: for 1 L of 20X stock--175.3 g NaCl (3 M), 88.2 g sodium citrate (0.3 M), use
DEPC water, adjust with NaOH to pH 7.0 (final), autoclave, store at RT
SSPE: for 1 L of 20X stock-174 g NaCl (3.6 M), 27.6 g Na^PC^ (0.2 M), 7.44 g
EDTA (20 mM), pH 7.4 (final), use DEPC water, autoclave, store at RT
Stacking gel: for one 1.5 mm gel-0.975 ml of 30% Acrylamide-Bis (4°), 1.25 ml of
1 M Tris pH 6.8 (4°), 7.675 ml distilled water, 0.1 ml of 10% SDS, degas for 10 min,
then add 50 ul of fresh 10% ammonium persulfate (10% made by adding 10 mg to
100 ul water) and 10 ul TEMED, let solidify for 2 hr
TAE loading buffer: for 1 ml—200 mg Ficoll (20%), 4 mg bromophenol blue
(0.4%), 4 mg xylene cyanole (0.4%), 1 ml of 10X TAE buffer, store at -20°C
TAE buffer: for 1 L of 10X stock- 48 g Tris (0.4 M), 6.8 g sodium acetate (50
mM), 3.72 g EDTA (10 mM), pH 8.0 (final), store at RT
Tank buffer: for 6 L-18.17 g Tris-HCl (25 mM), 86.46 g glycine (192 mM), 60 ml
of 10% SDS (0.1%), store at 4°C
TE: for 10 ml-100 ul of 1 M Tris-HCl (0.01 M) pH 8.0, 20 ul of 0.5 M EDTA (0.001
M) pH 8.0, store at RT
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Treatment buffer: for 10 ml of 2X stock-1.25 ml of 1 M Tris-HCl (0.125 M) pH
6.8, 4 ml of 10% SDS (4%), 2 ml glycerol (20%), 1 ml 2-mercaptoethanol (10%), 40
mg bromophenol blue (0.4%), store at -20°C
Trypsin: for 1 L of 10X trypsin-EDTA—5 g trypsin (0.5%), 2 g EDTA (5.3 mM),
dilute to IX in IX PBS before use, store at -20°C
Water saturated phenol: saturate with approximately an equal amount of DEPC
water by shaking at 37°C for several hours, store at 4°C
Western electrophoresis transfer buffer: for 4 L-12.11 g Tris-HCl (25 mM), 57.6 g
glycine (192 mM), 800 ml methanol (20%), bring volume to 4 L, store at 4°C
Western ligand blot buffer A: for 1 L-8.7 g NaCl (0.15 M), 5 ml of 2 M Tris-HCl
(0.01 M) pH 7.4, 500 mg NaN3 (0.5 mg/ml), 30 ml NP40 (3%), store at 4°C
Western ligand blot buffer B: for 1 L-8.7 g NaCl (0.15 M), 5 ml of 2 M Tris-HCl
(0.01 M) pH 7.4, 500 mg NaN3 (0.5 mg/ml), 10 g BSA (1%), store at 4°C
Western ligand blot buffer C: for 1 L-8.7 g NaCl (0.15 M), 5 ml of 2 M Tris-HCl
(0.01 M) pH 7.4, 500 mg NaN3 (0.5 mg/ml), 1 ml Tween 20 (0.1%), store at 4°C
Western ligand blot buffer D: for 1 L-8.7 g NaCl (0.15 M), 5 ml of 2 M Tris-HCl
(0.01 M) pH 7.4, 500 mg NaN3 (0.5 mg/ml), 10 g BSA (1%), 1 ml Tween 20 (0.1%),
store at 4°C
Western ligand blot buffer E: for 1 L-8.7 g NaCl (0.15 M), 5 ml of 2 M Tris-HCl
(0.01 M) pH 7.4, 500 mg NaN3 (0.5 mg/ml), 1 ml Tween 20 (0.1%), store at 4°C
Western ligand blot buffer F: for 1 L-8.7 g NaCl (0.15 M), 5 ml of 2 M Tris-HCl
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(0.01 M) pH 7.4, 500 mg NaN3 (0.5 mg/ml), store at 4°C
3.

Cells
The permanent clonal osteoblast-like cell line MC3T3-E1 [Kodama et al.,

1981], derived from newborn mouse calvarial cells and selected for its osteoblast
like features, was kindly provided by M. Kumagawa (Josai Dental Univ., Japan).
H-35 rat hepatoma cells (CRL 1548) used for the IGF-II RRA and mink
lung epithelial cells (MvlLu CC1-64) used for the TGF-beta assay were obtained
from ATCC (Rockville, MD).
DH5 competent bacteria were purchased from BRL (Gaithersburg, MD).
4.

Major Equipment
The water-jacketed incubators and -80°C freezers were purchased from

Forma Scientific (Marietta, OH). The laminar flow hoods for cell culture were
from Germfree Laboratories (Miami, FL). The inverted phase contrast microscope
(Epivert) was obtained from Leitz (Rockleigh, NJ). The L5-75B ultracentrifuge
with SW 41 rotor, the TJ-6 multi-tube centrifuge, the LS2800 (with 18-sample
racks) and LS8000 scintillation counters, the Gamma 5500 counter and the HPLC
reverse phase chromatography system using a model 344 gradient mixer were
purchased from Beckman (Fullerton, CA). The swinging bucket Centrific centri
fuge was bought from Fisher Scientific (Pittsburgh, PA). The Eppendorf 5415 C
microcentrifuge was acquired through Brinkmann (Westbury, NY). The Sorvall
RC-5B Superspeed centrifuge with GSA rotor (for 250 ml bottles, used adaptors for
50 ml tubes) was purchased from Du Pont (Wilmington, DE). The Lyph-lock 12
lyophilizer was bought from Labconco (Kansas City, MO). Speed vacs were from
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Savant (Farmingdale, NY). Ultrafiltration was performed with several sizes of
concentrators obtained from Amicon (Danvers, MA). Gel filtration was done with
columns from Bio-rad (Richmond, CA) and the following equipment from ISCO
(Lincoln, NE)-UA-5 absorbance monitor, retriever IV fraction collector and a type
6 optical unit. The dry shaker was purchased from Lab-line (Melrose Park, IL),
while the wet shaker was from Bellco (Vineland, NJ). The Lambda 3B spectropho
tometer was obtained from Perkin-Elmer (Cupertino, CA). The laser densitometer
was bought from Biomed Instruments (Fullerton, CA).

B.

METHODS

1.

Cell Culture

a.

Routine maintenance of MC3T3-E1 cells
1) Passaging: MC3T3-E1 cells were originally maintained in 10% FCS, but

several years ago they were switched to 10% calf serum and most recently 5% calf
serum to reduce cost. There was no apparent change in morphology after the
switches. When MC3T3-E1 cells reached 50-70% confluency they were passaged.
Briefly, DMEM with serum was aspirated off and cells were rinsed once with PBS
(2 ml/plate), followed by the addition of 1.5-2.0 ml of trypsin. Cells with trypsin
were then incubated at 37°C for 10-15 min, or until the cells sloughed off the Petri
dish. MC3T3-E1 cells were mixed with approximately an equal amount of DMEM
with serum and centrifuged at RT at 1000 rpm for 5 min in a Centrific centrifuge.
The medium was aspirated off to only leave a cell pellet. Cells were then vigorous
ly pipetted in DMEM with serum (usually 5 ml) to dissociate to a single-cell sus
pension and added to Petri dishes containing 10 ml of DMEM and serum. Typical
dilutions to last 3-4 days until the next passage were 1 to 5 or 1 to 10.
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2) Freezing: MC3T3-E1 cells were frozen in liquid nitrogen for future use
when the cultures were about 50% confluent. The passaging procedure was fol
lowed up to the cell pellet step. The cell pellet was resuspended in DMEM con
taining serum. An equal volume of 15% DMSO dissolved in DMEM containing
serum was then added and the cells were gently mixed. 1 ml aliquots were added to
cryovials which were then placed within a styrofoam insulating block (to slow the
freezing rate) at -80°C for at least overnight. The cells were then put in a liquid
nitrogen tank for long term storage (-196°C).
31 Thawing: MC3T3-E1 were removed from the liquid nitrogen tank and
immediately submerged in the 37°C water bath. After the cells had thawed (about
5 min), they were gently added to petri dishes containing 10 ml of DMEM with
serum. The following day, the medium was changed (to remove DMSO), after
which the cells were passaged normally.
b.

Culture procedures
1) Collection of conditioned medium: MC3T3-E1 cells were grown in

monolayer cultures in Petri dishes containing DMEM supplemented with 10%
serum. The cells were grown to confluence, rinsed twice with serum-free DMEM
and maintained in serum-free DMEM for CM collections. CM was collected every
two days for a total of 4-6 collections and then pooled to give 2-5 L of CM.
2) Cell proliferation assay: MC3T3-E1 cells were plated in 48-well plates at
a concentration of 10,000 cells per well in 0.5 ml of DMEM with 10% serum. After
48 hr, the medium was changed to serum-free DMEM after rinsing once with
serum-free medium. Growth factors were then added after an additional 24 hr
incubation in serum-free DMEM.
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3^ Induction of mRNA: MC3T3-E1 cells were maintained in DMEM con
taining 10% calf serum before switching to serum-free DMEM. MC3T3-E1 cells
were changed to serum-free medium when they became 60-80% confluent. The
cells were rinsed, incubated in serum-free medium for 24 hr and changed to fresh
serum-free medium 1 hr before the addition of growth factors. Cells were approx
imately 80% confluent when the growth factors were added.
2.

Biochemical Assays

a.

lodination of IGF-I and IGF-II
Both IGF-I and IGF-II were iodinated by a modification of the chloramine

T method of Goodman and Levy [1983] as described by Mohan et al. [1988c].
Briefly, 1 ug of either IGF-I or IGF-II was incubated with 1 mCi of Na^I in the
presence of chloramine T for 30-60 sec and then terminated by adding an excess of
cold potassium iodide. Iodinated protein was separated from unreacted Na^I
using a C^g Sep-Pak (Waters, Milford, MA). Aliquots were stored at -80°C. The
specific radioactivity of the iodinated IGFs was 150-300 uCi/ug protein.
b.

Radioimmuno assay for IGF-I
The IGF-I concentration in the samples was determined by RIA using

recombinant IGF-I as tracer and standard [Mohan et al., 1990b]. 200 ul RIA buffer
and 100 ul rabbit anti-human IGF-I antiserum (1° Ab, 1:6000 final dilution) were
added to polypropylene tubes containing IGF-I standard and unknown samples in
RIA buffer (100 ul). The tubes were shaken and incubated at RT for at least 60
min. 100 ul of tracer (30,000-45,000 dpm) was added and the tubes were incubated
overnight at 4°C. 200 ul of goat anti-rabbit antiserum (1:15 final dilution), 100 ul
of normal rabbit serum (1:20 final dilution) and 200 ul of 8% PEG (MW 8000)
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were then added to the tubes before a 2 hr incubation at RT. Tubes were then
centrifuged one time for 25 min at 2700 rpm with a TJ-6 centrifuge. The superna
tant was then decanted the radioactivity associated with the precipitate was counted
in a gamma counter. Some tubes were treated differently as follows; total count
tubes-only 100 ul tracer and 400 ul RIA buffer (no antisera or PEG), nonspecific
binding tubes--as normal except no 1° Ab and 400 ul RIA buffer, unbound--as
normal except 300 ul RIA buffer. The cross-reactivity of IGF-II in the IGF-I RIA
was less than 0.5% [Mohan et al., 1988c].
c.

Radioreceptor assay for IGF-II
The H-35 rat hepatoma cell line was selected for this assay since it has

abundant IGF-II receptors but no IGF-I receptors [Krett et al., 1987]. The IGF-II
RRA was performed as follows [Mohan et al., 1988c]. H-35 cells were plated in a
24 well culture plate at a concentration of 3 X 10^ cells per well in DMEM contain
ing 0.5% FCS. 24 hr after plating, the medium was removed and the cells rinsed
with 1 ml RRA binding medium to wash away any unattached cells. 220 ul of RRA
binding medium, 50 ul of sample and 20 ul of ^I-IGF-II (2 X 10^ dpm) were
added per well. The standard curve was produced by adding different concentra
tions of unlabeled human IGF-II (0.2-25.6 ng/well). After a 3 hr incubation at RT,
the radioactive medium was removed and the wells rinsed five times with 1 ml of
IX Hank’s buffer. Cells were lysed in 2 ml of RRA lysis buffer and the amount of
^^I-IGF-II present in the lysate was quantified by a gamma counter. The concen
tration of IGF-II in the unknown sample was determined by using the log-logit
method of Rodbard [1978] which calculated the displacement of ^I-IGF-II by
unlabeled IGF-II. The cross-reactivity of human recombinant IGF-I in the IGF-II
RRA was less than 2% [Mohan et al., 1988c].
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d.

Binding protein assay
The principle behind this assay is that PEG precipitates the large molecular

weight BP-IGF complex and not the small molecular weight IGFs [Elgin et al.,
1987]. This procedure was carried out as previously described [Mohan et al.,
1989c]. 50 ul of sample was incubated with 25,000-35,000 dpm of ^I-IGF-II for
60 min at RT in BP assay buffer (250 ul volume). Bound and free ^I-IGF-II
were separated by adding 100 ul of 2% bovine serum globulin and 500 ul of 25%
PEG (Molecular range 8000, dissolved in BP assay buffer) followed by centrifuging
for 20 min at 2700 rpm with a TJ-6 centrifuge. The supernatant was poured off, 500
ul of 15% PEG (dissolved in water) was added to each pellet and the samples were
centrifuged as before. Any excess liquid was removed from each pellet with a
cotton swab before counting in a gamma counter. Specific binding was calculated
by subtracting nonspecific counts in the precipitate from total counts.
e.

Cell proliferation assay
Growth factors were added to MC3T3-E1 cells after 24 hr of incubation in

serum-free DMEM. The cells were then pulse labeled 16-18 hr later for 2 hr with
0.75 uCi of

methyl-thymidine per well. The incorporation of

thymidine into

TCA precipitable material was used as a measure of DNA synthesis and was
determined as described [Mohan et al., 1986]. Briefly, labeled medium was re
moved and the plates were washed once with PBS. Cotton swabs were placed into
cardboard strips so that 4-6 wells could be swabbed at one time. The cotton swab
tips were dipped in 12.5% TCA and then the excess liquid shaken off. The tips
were applied to the cells with moderate force in a circular motion to remove all
cells attached to the plate. Next, the swabs were washed for 10 min, first in 12.5%
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TCA and then in 95% ethanol and allowed to dry. Finally, the swab tips were cut
off, placed in scintillation vials containing 1.5 ml of scintillation fluid (Ecoscint A)
and then counted to measure

thymidine incorporation.

thymidine incorpo

ration results were confirmed by counting the number of cells with a microscope in
some experiments.
f.

TGF-beta bioassay
TGF-beta was measured using mink lung epithelial cells [Jennings et al.,

1988]. Cells were maintained in DMEM with 10% FCS in 60-mm dishes and
passaged prior to confluence every 2-3 days. For the bioassay, 10,000 cells per well
were seeded into 48-well plates in 0.5 ml DMEM with 1% FCS. After 24 hr, factors
were added to replicate wells and incubated for another 30 hr. 0.75 uCi of
methyl-thymidine was added to each well and the plates were incubated for another
18 hr. TGF-beta standard (002-0.5 ng/ml for TGF-beta^ and 0.001-50 ng/ml for
TGF-beta2) was included in every assay. Inhibition of

thymidine incorporation

was plotted against the concentration of TGF-beta and one curve was used to calcu
late the amount of TGF-beta in the unknown sample. TGF-beta^ and TGF-beta2
were equipotent in inhibiting cell proliferation in these cells. The inhibition of
mink lung epithelial cell proliferation by TGF-beta was specific in that other known
growth factors (IGFs, PDGF, FGF) did not inhibit cell proliferation in this cell line.
To terminate the assay, the plates were rinsed and swabbed as described for the
mitogenic activity assay.
3.

Purification and Characterization of IGF Binding Proteins

a.

Separation of IGF BPs from IGFs
1) Ultrafiltration: CM was concentrated using a YM5 membrane (Amicon)
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to approximately 500 ml, acidified to 1 M acetic acid and then further concentrated
to 15 ml. All subsequent concentrations were carried out with YM5 membranes.
2) Acid gel filtration: The CM concentrate was divided into two samples
and each sample, in turn, was applied to a Sephadex G-100 column (2.5 x 100cm).
The proteins were eluted with 1 M acetic acid and 4-ml fractions were collected.
The acetic acid dissociated the IGFs from the BPs which eluted later than the BPs
due to their smaller molecular size. Fractions containing BP activity were pooled,
concentrated to a smaller volume using a YM5 membrane and lyophilized.
b.

Purification
1) IGF-I affinity chromatography: The lyophilized Sephadex active BP pool

was reconstituted in 100 ml of PBS and applied twice to the affinity column
(composed of recombinant human IGF-I coupled to CNBr-activated Sepharose 4B)
[Mohan, 1990a]. This column was used to separate the IGF BPs from other pro
teins. Unbound proteins were eluted with 100 ml of PBS and the bound proteins
were eluted with 50 ml of 4 M guanidine hydrochloride, 30 mM Tris pH 7.4.
2) HPLC RP CN: The IGF-I affinity bound fraction was concentrated in a
small Amicon, dialyzed against 3 volumes of 20 mM acetic acid and then subjected
to HPLC reverse-phase chromatography in 0.1% trifluoroacetic acid (TFA) using a
3.9 x 150 mm uBondapak CN column (Waters Chromatography, Milford, MA).
The unbound proteins were eluted for 5 min with 15% 1-propanol in 0.1% TFA.
Bound proteins were then eluted by a linear 15-45% 1-propanol gradient in 150
min and two-minute fractions were collected. Fractions were dried in a speed vac
concentrator, reconstituted in DMEM containing BSA and then tested in the BP
assay and the IGF-II RRA.
c.

Characterization
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1) Sequencing: BP sequences were determined by automated Edman
degradation using a Applied Biosystems model 470A vapor phase protein sequenc
er (Biotechnology Instrumentation Facility, University of California, Riverside).
PTH amino acids were analyzed with an on-line microbore HPLC. Data were
recorded and reduced with a Spectra physics model 4200 computing integrator.
2) Determination of molecular weight: In this procedure, the samples con
taining BPs were separated on SDS-PAGE and the proteins were transferred to
nitrocellulose membranes. The membranes were then incubated with ^I-IGF-II
and the MW of the BPs was determined by autoradiography of the ^I-IGF-II-BP
complexes. These steps are described below in detail.
a) Gel electrophoresis: A precast 3-27% gradient polyacrylamide gel was
assembled into the gel apparatus (higher % at bottom), the bottom of the comb was
placed about 0.5 cm above the precast gel, and the stacking gel was poured around
the comb. Extra stacking gel was continually added if any leaked out. Samples
(total 100 ul) were prepared by first adding an equal amount of treatment buffer
(2X), followed by boiling for 3 min. After the gel had solidified, the comb was
carefully removed and the samples were loaded into the wells. The gel chamber
was filled with tank buffer and the gel assembly was then placed into the gel
chamber. The buffer was circulated and kept at 4°C by a refrigerated circulator.
Samples were electrophoresed at a constant 13 millamps for about 16 hr (until dye
reached the bottom).
b) Western ligand blotting: After electrophoresis, both the gel and the
nitrocellulose membrane were soaked in Western transfer buffer for 10-15 min.
Whatman paper was also briefly soaked in the transfer buffer. The ligand blotting
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holder was carefully assembled in transfer buffer (avoiding bubble formation) in
this order-pad, whatman paper, nitrocellulose, polyacrylamide gel, whatman paper,
pad. The holder was then inserted into the chamber containing transfer buffer with
the nitrocellulose closest to the anode (red, positive) and the gel closest to the
cathode. The transfer was performed at 4°C (in the cold room) for 3 hr at a con
stant 50 volts. After transfer, the nitrocellulose membrane was dried for 5 min at
37°C. A series of incubations at 4°C (RT is okay for the shorter times) was then
performed with different buffers (100 ml unless stated otherwise) on a shaker set at
moderate speed as follows. The membrane was incubated with Western ligand
blotting buffer A for 30 min, Western ligand blotting buffer B for 2 hr, and then
Western ligand blotting buffer C for 10 min. The membrane was then incubated
overnight with 20 ml of Western ligand blotting buffer D containing 20 X 10^ dpm
of 1Z'JI-IGF-II. The membrane was then washed the following day with 200 ml of
Western ligand blotting buffer E for 15 min, followed by three separate washes with
Western ligand blotting buffer F for 15 min each. The membrane was air dried and
then exposed to pre-flashed x-ray film with one intensifying screen. Finally, the film
was developed after one week at -80°C.
4.

Molecular Biology Procedures

a.

Transformation of bacteria
DH5 competent bacteria were removed from the -80°C freezer and placed

on ice. 100 ul of cells were placed into a chilled polypropylene tube. 1-10 ng of
plasmid DNA (best when free of phenol, ethanol, protein and detergents) was
added by moving the pipette several times through the cells, followed by a gentle
shaking of the cells for 5 sec. The cells were then incubated on ice for 30 min and
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then heat shocked for 45 sec in a 42°C water bath (without shaking cells). The cells
were placed on ice for 2 min, then 0.9 ml of SOC medium (no antibiotic) at RT was
added. Cells were then shaken at 225 rpm (37°C) for 1 hr. Different amounts of
cells were then spread gently with a glass bar or loop on LB agar plates containing
the appropriate antibiotic and incubated at 37°C. (Note that transformation of
DH5 cells with 1 ng of pBR322 should yield at least 1 X 10^ colonies (amp-resist
ance).
b.

Plasmid preparation
This procedure was based on several methods described in Maniatis et al.

[1982b] and was used to prepare plasmid DNA for probes and transfection. Luria
broth contained the appropriate antibiotic in all of the following steps. Bacteria
from one colony were added to 10 ml of LB and incubated overnight in a shaker at
37°C. The 10 ml culture was then innoculated into 250 ml of LB and incubated
overnight as before. Alternatively, bacteria from a colony was added to 250 ml of
LB and then incubated for several days at 37°C. At this point aliquots of bacteria
were frozen down for long term storage. Bacteria in LB with antibiotic were mixed
with 80% glycerol to give a final concentration of 25% (up to 40% is also good). 1
ml aliquots were placed at -80°C (good for 1-3 yr). The plasmid preparation
procedure was then continued by centrifuging cells in 250 ml polypropylene bottles
at 5000 rpm at 4°C for 15 min using a GSA rotor. The pellet was completely resus
pended in 5 ml of lysozyme buffer, transferred to a 50 ml screw cap centrifuge tube
and allowed to stand at RT for 5 min. 10 ml of freshly made (important) 0.2 N
NaOH and 1% SDS was added to the tube and the tube was gently mixed by invert
ing several times. The tube was placed on ice for 10 min. 7.5 ml of 5 M potassium
acetate (3 M potassium, 5 M acetate) was added and the tube was incubated on ice
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for another 10 min. The 50 ml tube was centrifuged and the supernatant centri
fuged again at 10,000 rpm for 20 min at 4°C to pellet any non-plasmid DNA or
bacterial debris. The supernatants were then extracted two times with
phenol/chloroform/IAA pH 7.6 as follows. An equal volume of phenol/chloroform/IAA was added to the centrifuge tube. The tube was shaken vigorously for
30 sec and then placed on ice for 15 min. The tube was centrifuged at RT in a
Centrific centrifuge for 15 min at maximum speed. The aqueous layer was removed
(being careful not to disturb the interface) and extracted again with phenol/chloroform/IAA as before. 0.6 volumes of isopropanol was then added to the aqueous
layer and incubated at RT for 15 min. The DNA was recovered by centrifugation
at 10,000 rpm for 30 min at RT. DNA was resuspended twice in 500 ul TE contain
ing fresh DNase-free pancreatic RNase-A (20 ug/ml) and moved into microfuge
tubes. The RNase containing microfuge tubes were incubated for 15 min at 37°C.
After the incubation, 300 ul of 20% PEG 8000/2.5 M NaCl was added to each tube
and the tubes were placed on ice for 1 hr. The tubes were then spun for 5 min at
RT, the pellets rinsed twice with 70% ethanol and spun again for 5 min. The tubes
were put on the speed vac until dry and the pellets were resuspended in TE. The
concentration of plasmid DNA was estimated from spectrophotometer absorbance
readings at 260 and 280 run. The reading at 260 nm was multiplied by the dilution
factor and divided by 20 to give the amount of DNA in ug/ul. DNA was stored at
4°C for short time periods, but repeated freeze-thaw cycles from -80°C were
avoided.
c.

DNA restriction enzyme digestion
A typical restriction enzyme digestion reaction was set up as follows. 50 ug
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of DNA, 10 ul of 10X nuclease free BSA (10 mg/ml), 10 ul of 10X restriction
enzyme buffer, water and appropriate restriction enzymes (1-5 units enzyme/ug
DNA up to 10 ul) were added to give a final volume of 100 ul. The reaction mix
ture was then incubated overnight at 37°C in a water bath (in general, 1-2 hr incu
bations worked fine if 25 ug of DNA or less was digested).
d.

Low melting point gel
This procedure was done to separate the different sized DNA fragments that

were produced by the restriction enzyme digest. 0.75 g of low melting point agarose
was dissolved and microwaved in 45 ml distilled water. Then, 5 ml of 10X TAE
buffer and 6 ul of ethidium bromide were added. This solution was poured into a
11 x 14 cm gel apparatus and allowed to solidify. Samples were mixed with 2 ul of
TAE loading dye and electrophoresed until the restriction fragments separated
(determined by looking at ethidium bromide stain under uv light). The desired
band(s) were cut out with a razor blade, weighed, and then diluted with water (3 g
water/g agarose). DNA fragments were directly labeled from aliquots of the dilut
ed agarose. Hind III digested lambda was typically used as a size standard.
e.

DNA probes
11 Fos probe: Blots were analyzed for the presence of a 2.2 kb c-fos tran

script [Mueller, 1986] by hybridization with a 1000 bp v-fos gel-purified fragment
corresponding to the 3’ viral coding sequence (Oncor, Gaithersburg, MD).
2) Jun probes: c-jun cDNA probe (pcDIO) was a kind gift from Inder
Verma’s lab [Lamph et al., 1988]. This c-jun clone is 2,347 nucleotides long which
is in close agreement with the size of the mouse c-jun mRNA (2.7 kb), c-jun plas
mids were digested with Pst 1 to yield three bands. The largest band (2020 bp) was
removed and used for labeling which also contained the entire coding region . Both
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jun-B (#63025) and jun-D (#63024) cDNAs were obtained from ATCC (Rockville,
MD) and their inserts were cut out with EcoRI. jun-B cDNA was 1917 nucleotides
long and detected a 2.1 kb transcript [Ryder et al., 1988a], while jun-D cDNA was
1600 nucleotides in length and detected a 1.8 kb transcript [Ryder et al., 1989]. All
three jun probes used for hybridization contained the entire coding region plus
portions of the 5’ and 3’ non-coding sequences.
3) Actin probe: RNA loading was standardized for some blots using a
chicken beta-actin cDNA probe obtained from Oncor (Gaithersburg, MD).
4) Probe labeling: cDNA probes were labeled by using the random priming
method. This procedure was based on a method derived by Feinberg & Vogelstein
[1983], and developed into a commercial kit by Pharmacia (Piscataway, NJ). To
start with, 50 ng of cDNA in 31 ul water (warm first at 55°C if in agarose) was heat
denatured by boiling for 10 min and then put on ice for 5 min. The following
reagents were then added to yield a total reaction volume of 50 ul: 10 ul reagent
mix (contained 6-mer oligonucleotides), 2 ul BSA (DNase free), 50 uCi (about 5 ul)
alpha-^P-dCTP and 2 ul recombinant Klenow DNA polymerase fragment. This
was then incubated overnight at 22° C and terminated with 20 ul stop buffer (from
Pharamcia kit) and 180 ul water.
5) Separation of labeled probe: After labeling was completed, unincorpo
rated alpha-^P-dCTP was separated with a NAGS column (BRL, Gaitherburg,
MD). NAGS is an anion exchange column with tertiary amines bound to teflon
beads. For cDNA probes longer than 1000 bp, 750 ul of 0.5 M NaCl/TE was added
to the labeled cDNA. The column was hydrated with 3 ml of 2 M NaCl/TE and
equilibrated with 5 ml of 0.5 M NaCl/TE. For cDNA probes 1000 bp or less in

50

length, 0.2 M NaCl/TE was used instead of 0.5 M NaCl/TE. The cDNA mixture
was loaded two times on the column and then washed with 5 ml of 0.5 M NaCl/TE
to remove unincorporated alpha-^P-dCTP. Labeled cDNA was eluted with 400 ul
of 2 M NaCl/TE. A 2 ul aliquot was counted in a scintillation counter to determine
the specific activity.
f.

mRNA isolation and analysis
For induction experiments, IGF-I (10 ng/ml), IGF-II (10 ng/ml) or TGF-

beta (100 pg/ml) were added to about 80% confluent MC3T3-E1 cells. Cells were
treated with factors for a fixed time, typically 0, 15, 30, 60, 120 and 240 min.
1) RNA extraction with GIT: Total RNA was extracted in GIT buffer at the
end of each time point as follows. The cells were removed from the incubator and
the medium was completely aspirated off. The amount of GIT buffer per time
point (maximum 8 ml) was selected to allow for sample volume limitations for the
ultracentrifugation step. For a typical experiment of six plates per time point, 1 ml
of GIT buffer was immediately added to all but the last plate which received the
remaining 3 ml. Starting with the last plate, the cells were then thoroughly scraped
to one side and transferred to the next plate. This was done until the cell extracts
from all six plates were in one plate which was then transferred to a 15 ml screw
cap polypropylene centrifuge tube for freezing at -80°C (one overnight freeze-thaw
cycle appeared to increase RNA yields).
2) RNA isolation: The cell extracts from each time point were carefully
layered on top of 4 ml of CsCl buffer making sure that the ultracentrifuge tubes
were filled to the top (extra GIT buffer was used if needed). Samples were then
spun in an ultracentrifuge using a SW 41 rotor at 30°C (temperature range of 25-35
°C on machine) for 22 hr at 36,000 rpm (220,000 g) [Chirgwin et al., 1979]. After
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centrifugation, the RNA formed a pellet (usually invisible) at the bottom of the
tube. DNA was visible as a stringy mass in the lower part of the tube, while the
protein was found in the top of the tube. The entire supernatant was carefully
removed and 400 ul of 0.3 M sodium acetate was added before vortexing several
times over a 10-15 min period. This liquid was removed to a microfuge tube. The
preceding step was repeated again by adding another 400 ul of sodium acetate to
the ultracentrifuge tube and transferring it to a separate microfuge tube. 1 ml of
absolute ethanol was then added to each tube and the tubes were placed at -20°C
overnight. The RNA was centrifuged in a microcentrifuge for 10 min at 4°C and
the liquid covering the RNA pellet was carefully removed. 300 ul of 80% ethanol
was layered over the pellet and the tubes were centrifuged for 2 min at 4°C. The
pellet was dried in a speed vac for a few minutes and then resuspended in DEPC
water or TE (typically in 50 ul). RNA was quantitated on a spectrophotometer by
multiplying the 260 nm absorbance reading by the dilution factor and dividing it by
25. If the ratio of RNA (260 nm) to protein (280 nm) was greater than 1.4, the
sample was then used for Northern analysis. Typical RNA yields were 10 ug per
plate or about 60 ug per time point.
31 Northern gel: For this procedure, a denaturing 1.5% "minigel" (5.5 X 8
cm) was prepared as follows. 0.23 g agarose was added to about 10 ml of DEPC
water and then microwaved until thoroughly dissolved and bubble free. This was
combined with 3 ml of 5X MOPS (final IX), 2.7 ml of 37% formaldehyde (final
6.6%) and enough water for a total volume of 15 ml. Samples were prepared by
adding 2 ul of RNA (in water or TE), 1 ul of 5X MOPS, 1.7 ul of 37% formalde
hyde and 5 ul of formamide, followed by incubation for 15 min at 55°C. Samples
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were then plunged in ice and 2 ul of Northern loading buffer was added. The
samples were then added to the gel using IX MOPS as a running buffer and electrophoresed at 80 V for about 2 hr until the bromophenol blue reached the bottom
of the gel [Lehrach et aL, 1977]. RNA was transferred overnight to Nytran by capil
lary action with 10X SSC and immobilized by heating for 45 min at 75° C
[Schleicher & Schuell, 1987].
4) Uniform loading: To standardize for uniform RNA loading, blots were
either probed with chicken beta-actin c DNA as indicated below, or stained with
methylene blue [Herrin & Schmidt, 1988]. The methylene blue staining procedure
was done as follows. Blots were prewetted with IX SSPE and then stained for 2
min with methylene blue stain. Non-specific staining was removed with DEPC
water. Blots were then photographed and then completely destained with 0.2X
SSPE and 1% SDS before hybridization.
5) Hybridization and autoradiography: The RNA blots were prehybridized
in 4 ml of 50% formamide, 5X SSPE, 5X Denhart’s, 200 ug/ml denatured herring
sperm DNA, and 0.1% SDS for 2-4 hr at 42° C. Hybridizations were carried out
for at least 24 hr at 42° C in 2 ml of prehybridization solution including 10% dextran sulfate and 1-2 X 10^ dpm/ml ^P cDNA probe. The filter was then washed
twice in 6X SSPE, 0.25% SDS for 15 min at 42° C, followed by further washes in
IX SSPE, 0.25% SDS for 15 min at 42° C.

Filters were autoradiographed with

preflashed (two times) x-ray film and a Cronex III intensifying screen for 3-5 days at
-80° C. Finally, autoradiographs were quantified with a laser densitometer by
scanning each lane of photographs of uniform loading (usually methylene blue
stains) and the corresponding autoradiograph. The ratio of the two scans were then
compared to normalize hybridization to amount of RNA transferred.
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g-

Transfection
MC3T3-E1 cells (200,000) were plated in a 60-mm culture dish in 5 ml

DMEM with 10% calf serum. The cells were incubated at 37°C until they reached
50% confluency. 7.5 ug of either mouse fos sense or anti-sense DNA was diluted in
1.5 ml Opti-MEM I, while 20 ul of lipofectin was diluted in an additional 1.5 ml
Opti-MEM I. Polystyrene tubes were used to prevent the lipofectin from sticking to
the tube surface. The diluted DNA and lipofectin solutions were then combined.
The DMEM from the MC3T3-E1 cells was removed and the cells were washed only
once with 3 ml of Opti-MEM I before the 3 ml DNA-lipofectin solution was added
to each plate. The cells were incubated for 5 hr at 37°C, then 3 ml of DMEM with
20% calf serum was added. After 24 hr, the antibiotic geneticin (400 ug/ml) was
added to the cells to select for stable transfectants. Initially, most of the cells died
within 3 days (95%), but after a week of selection transfected colonies became
readily observable. Selection in geneticin was continued for the duration of the
experiments. Transfected cells were used in the cell proliferation assay to test the
effects of IGF-H. 1 uM of dexamethasone was used to stimulate transcription from
the fos constructs.

III. RESULTS

A.
1.

PURIFICATION AND CHARACTERIZATION OF BONE GROWTH
REGULATORS
Collection of Conditioned Medium
Initial studies showed that CM collected from MC3T3-E1 cells stimulated

proliferation of embryonic chick calvarial cells (results not shown). These results
suggested that MC3T3-E1 cells in culture produce factors that are mitogenic to
bone cells. To characterize growth factors produced by MC3T3-E1 cells, CM col
lections (2-5 L/batch) were made from confluent serum-free MC3T3-E1 cell cul
tures. A total of 16 different CM batches were collected which had a protein
concentration ranging from 1.6-2.9 mg/L CM. Usually, CM collection was contin
ued for as long as the cells remained viable which typically lasted 10-14 days.
Occasionally, there were problems with yeast or fungal contamination, especially
after the MC3T3-E1 cells were serum-free for more than a week. Initial experi
ments to characterize the bone growth factors present in MC3T3-E1 cell CM
showed that the CM contained approximately 0.8 ug/L CM of IGF-I as determined
by IGF-I RIA, 1.2 ug/L CM of IGF-II as measured by IGF-IIRRA and 0.05 ug/L
CM of TGF-beta as measured by the TGF bioassay.
2.

Separation of IGF BPs from IGFs
Since bone cells in culture make IGF BPs which produce artifacts in IGF

radioligand assays [Mohan et al., 1990b], a purification scheme was designed to
separate the IGF BPs from the IGFs. This was done to verify that the IGF-I RIA
and IGF-II RRA activities found in crude MC3T3-E1 cell CM belonged to the
IGFs and were not due to IGF BP artifacts. A summary of this purification scheme
is outlined in Fig. 1. To begin the purification scheme, 2-5 L of MC3T3-E1 cell CM
was first concentrated to about 15 ml then subjected to Sephadex G-100 gel
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filtration chromatography in 1 M acetic acid to separate the low MW IGFs from the
higher MW IGF BPs. A typical Sephadex G-100 protein profile recorded by
measuring the absorbance at 280 nm (Fig. 2) yielded a major peak which eluted
before the 67 kDa MW marker followed by a minor peak between the 67 and 17.8
kDa MW markers. ^I-IGF-I was used as a marker to determine the elution
position of IGF-I under the conditions used in this work.
IGF-I RIAs and IGF-II RRAs were performed to determine which fractions
contained the IGFs. The IGF-II RRA was also used to measure In-IGFBP activity
since previous studies had shown that In-IGFBP could bind to 125I-IGF-n and
prevent tracer from binding to the cell receptors in a similar manner as cold IGF-II
could by competing with tracer for receptor binding. In this representative batch of
CM, IGF-I activity eluted between fractions 73-87 (Fig. 3) with fraction 83 exhibit
ing peak IGF-I activity. Fractions that contained IGF-I RIA activity corresponded
to the position where authentic ^I-IGF-I eluted.
IGF BP activity (determined later to be MC-IGFBP-2 activity) as deter
mined by the inhibition of ^I-IGF-II binding to H-35 cells in the IGF-II RRA
eluted between fractions 45-56 (Fig. 4). Peak activity eluted around fraction 52
between the MW markers of 45.8 and 17.8 kDa. In contrast to IGF-I, there was no
significant IGF-II RRA activity peak in the region where authentic IGF-II eluted.
This was probably due to the decreased sensitivity of the IGF-II RRA compared to
the IGF-I RIA.
Based on these results and on the data from the MW size markers, fractions
were then combined into two pools-one containing the IGFs and another pool
containing the IGF BP(s). In this experiment, fractions 69-90 (Fig. 3) were selected
to form the IGF pool, while fractions 41-64 (Fig. 4) were chosen to form the BP
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pool. Fractions included in the BP pool were carefully chosen to avoid contamina
tion with the IGFs.
3.

Affinity Purification of the IGFs and IGF BPs
The BP pool (3 mg of protein from 4.7 L CM) was then applied to an IGF-I

affinity column (Fig. 1) to separate the IGF BPs from other proteins found in the
pool. This column was chosen since previous studies had shown that the majority of
IGF BPs bind to both IGF-I and IGF-II with near equal affinity and also since
recombinant human IGF-I was available at that time [Mohan & Baylink, in press].
Bound proteins were eluted with 4 M guanidine hydrochloride and contained about
2 ug of BP activity (in IGF-II equivalents) as measured by IGF-II RRA. The
unbound fraction contained no detectable amount of BP activity.
The low MW Sephadex G-100 IGF pool containing IGF-I and II was applied
to an IGF-Ab affinity column to further purify the IGFs. This column was selected
since previous studies had shown that both human IGF-I and IGF-II bind with high
affinity to Sm 1.2 monoclonal antibodies used in this column [Mohan, 1990a]. IGFI and IGF-H measurements were made in the bound and unbound fractions by RIA
and RRA, respectively. IGF-II bound to the affinity column (.19 ug), however IGFI did not (1.9 ug). The lack of IGF-I binding from MC3T3-E1 CM could be ex
plained by the fact that the antibodies used in the affinity column were made
against human IGF-I in mice [Chernausek et al., 1985].
4.

Characterization of IGF BPs
One preparation of IGF BP that was purified by Sephadex G-100 and IGF-I

affinity chromatography was used for N-terminal amino acid sequence analysis (Fig.
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5). The sample was prepared for sequencing by applying it to an Immobilon
membrane. Analysis of the sequence data revealed that this IGF BP preparation
was not homogeneous as it produced two sequence signals, a major and a minor
signal. Comparison of these sequences with those of known IGF BPs revealed that
the major sequence signal (sequence 1 in Fig. 5) was similar to the N-terminal
sequence of an IGF BP called CSF BP which is found in cerebrospinal fluid and
human skin fibroblast CM [Roghani et al., 1989; Martin et al., 1990]. The second
sequence (minor sequence corresponding to sequence 2 in Fig. 5) was similar to the
N-terminal sequence of In-IGFBP [Mohan et al., 1989c]. The major BP (MCIGFBP-1) appeared to be approximately 3 times more abundant than the minor BP
(MC-IGFBP-2) based on the recovery of the first two N-terminal amino acids
sequenced (Fig. 5). The presence of two different binding proteins in MC3T3-E1
cell CM was further confirmed by Western ligand blotting of partially purified CM
which yielded two distinct bands (Fig. 6, lane A).
Because sequence studies and Western ligand blotting provided evidence for
more than one IGF BP in the IGF-I bound fraction, it was decided to separate
these two BPs by using HPLC RP chromatography for the following reasons. First,
HPLC RP chromatography is one of the most efficient way to separate proteins.
Second, both CSF BP and In-IGFBP activity had been found to be resistant to
HPLC solvents originally used to purify them.
The bound fraction from the IGF-I affinity column was subjected to HPLC
RP chromatography using a CN column with a 1-propanol gradient. HPLC frac
tions were assayed for BPs by using the IGF-IIRRA and BP assay. The IGF-II
RRA was used to measure MC-IGFBP-2 since it, like cold IGF-II, competes for
125 I-IGF-II binding to the H-35 cell receptors. In comparison, the BP assay was
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used to identify MC-IGFBP-1 since its biological action was unknown. If the bio
logical action of MC-IGFBP-1 was stimulatory it would complex with ^I-IGF-II
and still bind to the IGF-II receptors. In this case, MC-IGFBP-1 would not compete
for l^I-IGF-II binding to the receptors and thus would remain undetectable in the
IGF-II RRA. In the BP assay, IGF BP activity was measured by precipitating the
complex of ^I-II and BP with PEG and counting the radioactivity associated with
this precipitate. Fractions that contained BP activity were then concentrated by
speed vac and used for Western ligand blotting.
HPLC RP chromatography of IGF-I affinity purified IGF BPs resolved the
two IGF BPs as determined by Western ligand blotting (Fig.6). IGF-II RRAs and
BP assays were first performed on the HPLC RP fractions to determine the
fractions to be loaded for Western ligand blotting. MC-IGFBP-2 (lane B) eluted in
fraction 41 (30.4% 1-propanol) while MC-IGFBP-1 (lane C) eluted in fraction 56
(36.4% 1-propanol). MC-IGFBP-2 was inhibitory in the IGF-II RRA while MCIGFBP-1 was less potent in inhibiting IGF-II to the receptors. The MW of these
BPs, based on the autoradiograph of the Western ligand blot, were 32 kDa for the
MC-IGFBP-1 and about 25 kDa for the MC-IGFBP-2. This estimate is close to the
reported 34 kDa MW of the CSF BP [Roghani et al., 1989] and is in agreement
with the MW of 25 kDa for the In-IGF BP [Mohan et al., 1989c].
5.

Partial Purification of TGF-beta
Another important bone growth factor found in MC3T3-E1 CM was TGF-

beta as measured by the mink lung TGF-beta bioassay. TGF-beta was partially
purified by first acidifying the CM with 1 M acetic acid followed by Sephadex G-100
chromatography (Fig. 7). The CM was acidified to activate the latent form of
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TGF-beta (major form) so that the TGF-beta activity could be measured. Activity
was found in fractions 48-70 with maximal inhibitory activity occurring at fraction
53. In this assay both TGF-betal and TGF-beta2 were equipotent in inhibiting
mink lung cell proliferation.
6.

Relative Distribution of IGF BPs, IGFs and TGF-beta
Fig. 8 summarizes the abundance of the various bone growth regulators

found in MC3T3-E1 CM after purification with affinity chromatography. Levels of
IGF-I were determined by RIA, while IGF-II levels were determined by RRA using
human standard in both assays. Results are from medium conditioned for 48 hr.
Since different assays were used, the results should be carefully interpreted. IGF
BPs and IGF-I seemed to be most abundant, while IGF-II was found at 1/10 of IGF
BP and IGF-I levels. TGF-beta was found to be about twice as abundant as IGF-II.
Based on the picomole information from the sequence data in Fig. 6, MC-IGFBP-1
appeared to account for approximately 75% of BP activity while MC-IGFBP-2
accounted for the remaining 25% BP activity. It should be noted that the IGF BP
concentrations are not actual amounts but represent ng IGF-II equivalents as
determined by the inhibition of 125I-IGF-II binding by IGF BP in the IGF-II RRA.

B.

BIOLOGICAL ACTIONS OF BONE GROWTH REGULATORS MADE BY
MC3T3-E1 CELLS-AUTOCRINE ACTION
The effects on MC3T3-E1 cells of the bone growth factors known to be made by

MC3T3-E1 cells were investigated. This was done to determine if factors made by
MC3T3-E1 cells could in turn act on MC3T3-E1 cells in an autocrine manner.
Dose response experiments measuring

thymidine incorporation were performed
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with IGF-I, IGF-II and TGF-beta. Counts of cell numbers confirmed the
thymidine incorporation data. A dose response curve for IGF-I (Fig. 9) was done
by testing four different concentrations of IGF-I-0.4, 2, 10 and 50 ng/ml. IGF-I
maximally stimulated

thymidine incorporation at a concentration of 10 ng/ml (p

< .001) to 320% of control. The minimum effective dose for IGF-I was 2 ng/ml
which stimulated

thymidine incorporation to 154% of control.

A similar experiment was performed with IGF-II (Fig. 10) using doses of 0.6,
2, 10 and 30 ng/ml. In contrast to IGF-I, maximal stimulation for IGF-II was found
at 30 ng/ml (236% of control, p < .001). The minimum effective dose for IGF-II
was likewise found to be 2 ng/ml which stimulated

thymidine incorporation to

143% of control. Thus, of the two IGFs, IGF-I was found to be slightly more potent
than IGF-II.
In addition to the IGFs, TGF-beta was tested on MC3T3-E1 cells (Fig. 11)
at concentrations of 1,10, 50,100 and 500 pg/ml. All doses of TGF-beta tested
inhibited

thymidine incorporation, with maximal inhibition occurring at 500

pg/ml (21% of control, p <.01). Even concentrations as low as 1 pg/ml were found
to inhibit

thymidine incorporation in MC3T3-E1 cells to 46% of control.

Therefore, TGF-beta was the most potent growth regulator that was found to be
secreted by MC3T3-E1 cells.
C.
1.

MOLECULAR BIOLOGY STUDIES
c-Fos Proto-oncogene
Since IGF-I and IGF-II increased cell proliferation, while TGF-beta de

creased proliferation, it was proposed that this difference might be due to a meas
urable change in an intracellular signal as indicated in Fig. 12. This idea was based
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on an earlier study by Ruether et al. [1987] which showed that when the proto
oncogene c-fos was expressed at high levels in transgenic mice, multiple lesions of
increased bone formation developed with no visible effects on other tissues. Since
MC3T3-E1 cells are mouse bone cells, it was hypothesized that the IGFs and TGFbeta might mediate their effects on MC3T3-E1 cell proliferation by modulating the
induction of c-fos. Accordingly, the hypothesis was proposed that IGF-I and IGFII, stimulators of MC3T3-E1 cell proliferation, might induce c-fos gene expression,
while TGF-beta, an inhibitor of MC3T3-E1 cell proliferation, might inhibit basal cfos gene expression.
Quiescent MC3T3-E1 cells were treated with growth factors for various time
periods ranging from 15 min to 6 hr to measure their effects on the expression of
fos and jun proto-oncogenes. Growth factor concentrations were used that signifi
cantly changed DNA synthesis as measured by

thymidine incorporation.

Accordingly, for the induction experiments, 10 ng/ml of IGF-I and IGF-II (p
<.001) and 100 pg/ml of TGF-beta (p <.01) were added to serum-free cultures of
MC3T3-E1 cells.
Effects of IGF-I and IGF-II on c-fos mRNA levels of quiescent MC3T3-E1
cells were examined at 15, 30, 60,120, and 240 min by extraction of total RNA and
Northern blot hybridization in two separate experiments. IGF-I increased levels of
the 2.2 kb c-fos transcript at 15 and 30 min as seen on a Northern blot (Fig. 13).
Maximal induction was about 25-fold at 15 min. At 60 min, c-fos message was still
detectable. No transcripts were detectable at 0 and 120 min.
Fig. 14 shows Northern analysis results from an induction of MC3T3-E1 cells
with IGF-II. Like IGF-I, IGF-II also induced c-fos at 15 and 30 min, with a maxi
mal 25-fold increase at 30 min. By 60 min the c-fos transcript had largely
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disappeared, and no transcripts were detectable at 0 and 120 min.
MC3T3-E1 cells were treated with TGF-beta for 30, 60,120, 240 and 360
min (Fig. 15) in two separate experiments, c-fos mRNA levels were increased 7fold at 30 and 60 min. mRNA transcripts were undetectable at the other time
points.
In order to determine if c-fos is directly involved in cell proliferation,
MC3T3-E1 cells were transfected with murine sense (pM84foss) or antisense
(pM84fosas) constructs that contained the dexamethasone-inducible MMTV
promoter [Holt et al., 1986]. Both constructs contained a 84 bp fragment from the
mouse c-fos promoter. Stable transfectants were selected with the antibiotic G418.
MC3T3-E1 cells that were stably transfected with either sense or anti-sense con
structs were tested in the cell proliferation assay. The promoters of the transfected
cells were induced with dexamethasone to see if sense fos might stimulate and antisense fos might inhibit cell proliferation.
Dexamethasone (1 uM) was added to transfected and untransfected MC3T3E1 cells at various time points (0, 2, 4, 8 and 24 hr) before addition of

thymidine

(18 hr incubation) to measure cell proliferation. Cells treated with dexamethasone
at the beginning of

thymidine incubation (both normal and transfected) had

thymidine incorporation levels about 80% that of untreated cells (results not
shown). In all cases,

thymidine incorporation levels steadily dropped as

dexamethasone treatment times increased from 0 to 8 hr (40% of control at 8 hr).
Untransfected and sense transfected cells showed a further 5% decrease of
thymidine incorporation at 24 hr. In contrast, anti-sense cells showed a 10-15%
increase in

thymidine incorporation from the 8 hr to the 24 hr timepoint.
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Dexamethasone treated cells (normal and untransfected) were proportionally stimu
lated by IGF-H (only growth factor tested) at all timepoints as much as untreated
cells were stimulated by 18 hr of IGF-II incubation.
2.

Jun Family Proto-oncogenes
Since it had been shown that fos protein dimerizes with another family of

nuclear proteins called Jun [Curran & Franza, 1988], mRNA levels of the original
member, c-jun, were investigated. In these experiments, IGF-I, IGF-II, and TGFbeta were added to MC3T3-E1 cells for 15, 30, 60,120 and 240 min. Experiments
with the IGFs were performed twice. 2.7 and 3.2 kb c-jun transcript levels was
found to be constitutively expressed. Neither IGF-I (Fig. 16) nor TGF-beta (Fig.
18) increased c-jun mRNA when the Northerns were corrected for RNA loading as
determined by laser densitometry. However, IGF-II (Fig. 17) increased c-jun
mRNA levels 5-fold at 15 min, 11-fold at 30 min, and 13-fold at 60 min. At later
time points, c-jun levels returned to basal level.
Northern analysis was also performed with another member of the jun
family called jun-B [Ryder et al., 1988a]. jun-B transcript levels were undetectable
after treatment with either IGF-I (Fig. 19) or IGF-II (Fig. 20). In contrast, TGFbeta (Fig. 21) increased the levels of the 2.1 kb jun-B transcript 9-fold at 30 min
with a maximum of 24-fold at 60 min. mRNA levels then dropped to 18-fold at 120
min and 8-fold at 240 min.
Blots were also probed with the most recent member of the jun
family--jun-D [Ryder et al., 1989]. IGF-I (Fig. 22) and TGF-beta (Fig. 24) had little
effect on the constitutive expression of the 1.8 kb jun-D transcript. In contrast,
IGF-II (Fig. 23) increased jun-D mRNA levels 5-fold at 15 min and 4-fold at 30
min. jun-D levels at other time points were constitutive.
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A frequent problem with Northern blot analysis is quantitating the amount
of RNA transferred from the gel to the filter. Previous investigators have used
probes to examine messages that are "unchanging" in their experiments. Actin is
frequently used as a standard, but actin mRNA levels can be induced under some
conditions, e.g. EGF stimulated AKR-2B mouse embryo cells [Elder et al., 1984].
The recently described methylene blue staining method [Herrin & Schmidt, 1988]
was found in this work to be reliable based on direct comparison of hybridization
with actin and staining with methylene blue. This method allows RNA loading
information to be obtained in a half hour instead of at least one week which is
required with traditional hybridization techniques.
3.

c-Myc Proto-oncogene
Northern blots were also probed with a commercially obtained human c-myc

probe (Oncor, Gaithersburg, MD) and then with a murine c-myc probe (ATCC,
Rockville, MD). In either case, the probe was unable to detect any c-myc tran
scripts. However, the probes were able to detect c-myc mRNA from human
leukemia HL-60 cells which are known to abundantly produce c-myc mRNA [Col
lins & Groudine, 1982]. Thus it appears that in MC3T3-E1 cells c-myc is made at
very low levels if at all.
4.

Summary
Fig. 25 summarizes the data from all of the Northern analyses that were

done. Values were determined with a laser densitometer that measured both area
and intensity of the bands. The data from the transcripts were then adjusted to
compensate for the actual amount of RNA loaded (found in the lower panel of
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each Northern blot). Briefly, IGF-I and IGF-II were found to maximally increase cfos transcript levels in MC3T3-E1 cells at 15 and 30 min, while TGF-beta increased
c-fos levels at 30 and 60 min. Both c-jun and jun-D levels were found to be constitutively expressed, except that IGF-II was able to increase c-jun levels from 15 min
to 60 min and jun-D levels at 15 and 30 min. jun-B transcripts were undetectable at
any time with the IGFs, while TGF-beta increased jun-B from 15 to 240 min with a
maximum induction at 60 min.
The actions of IGF-I, IGF-II and TGF-beta on proto-oncogene expression
and cell proliferation in MC3T3-E1 cells are summarized in Fig. 26. For the sake
of simplicity, only the most dramatic effects of the growth factors on proto-onco
gene expression are indicated, namely c-fos and jun-B.

66
Figure 1. Purification scheme for IGF binding proteins and IGFs from
MC3T3-E1 cells. IGF BPs and IGFs were purified from batches of serum-free CM
(about 5 L) that were concentrated and dialyzed by Amicon filtration before gel
filtration chromatography. HPLC RP chromatography was done with either a C4
column using an acetonitrile gradient or a CN column using a 1-propanol gradient.
Characterization of IGF BPs was performed by N-terminal amino acid sequencing
and Western ligand blotting.
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Figure 2. Sephadex G-100 gel filtration of MC3T3-E1 conditioned medium:
protein profile. 10.5 mg of protein in 15 ml was loaded and the proteins were
eluted with 1 M acetic acid. 4 ml fractions were collected. MW markers eluted at
fraction 39 for BSA (67 kDa), fraction 50 foLOvalbumin (45.8 kDa), fraction 56 for
myoglobin (17.8 kDa) and fraction 83 for ^I-IGF-II (7.5 kDa). Arrows indicate
the various MW markers.

69

E

c
o
oo
CM

CO

CD

O

c

(0
_Q
O
<0
JQ
<

20

30

40

50

60

70

Fraction Number

80

90

70

Figure 3. Sephadex G-100 gel filtration of MC3T3-E1 conditioned medium:
IGF-IRIA. Recomoinant IGF-I was used as tracer and standard in the IGF-IRIA.
An aliquot of each fraction was dried down to remove acid and tested for activity.
Results are caressed as the percentage of tracer bound to antibody in the presence
of sample divided by maximum tracer bound in the absence of competitors i.e.,
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Figure 4. Sephadex G-100 gel filtration of MC3T3-E1 conditioned medium:
IGF-IIRRA. HPLC RP purified IGF-II from human femoral bone samples, was
used as tracer and standard in the IGF-II RRA. An aliquot of each fraction was
dried down to remove acid and tested for activity in the absence of added IGF-I.
Results are expressed as in Fig. 3, except that tracer was bound to H-35 cell
receptors rather than to antibodies. Addition of IGF-I, which blocks the effects of
IGF BPs in the assay, inhibited activity in all fractions, indicating that IGF-II levels
were below the level of detectability (8 ng/ml).
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Figure 5. N-terminal amino acid sequences from IGF-I affinity-purified
MC3T3-E1 CM. Sequence 1 corresponds to MC-IGFBP-1 (CSF BP), while
sequence 2 corresponds to MC-IGFBP-2 (In-IGFBP). 100 pmol of sample was
sequenced. The initial yield was 19.7% and the average repetitive yield was 96.7%.
X means no definitive yields were observed.
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31.0
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Figure 6. Western ligand blot of IGF BPs isolated from MC3T3-E1 cells.
Lane A contains an aliquot from the Sephadex G-100 IGF BP pool. Lane B
contains fraction 41 an d lane C fraction 56 from HPLC RP using a CN column with
a 15-45% isopropanol gradient collected in 2 ml fractions over 150 min. Lane B
corresponds to the In-IGF BP while lane C corresponds to MC-IGFBP-1 based on
sequence analysis and published MWs. Arrows indicate the MW markers
ovalbumin (43 kDa), carbonic anhydrase (29 kDa) and alpha-lactoglobulin (18
kDa).
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Figure 7. Sephadex G-100 gel filtration of MC3T3-E1 conditioned medium:
TGF-beta bioassay. Commercially obtained TGF-beta was used as standard. An
aliquot of each fraction was dried down to remove acid and tested for activity in
mink lung epithelial cells. Results are means of six replicates and are expressed as
thymidine incorporation into TCA insoluble material, % of solvent-treated
control.
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Figure 8. Growth regulators found in MC3T3-E1 conditioned medium.
IGF-I was measured by RIA, IGF-II and IGF BP by RRA and TGF-beta by
bioassay subsequent to affinity chromatography purification of medium conditioned
for 48 hr.
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183
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30

68
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Figure 9. IGF-I dose response in MC3T3-E1 cells. Values are expressed as
percentage of unstimulated control and are mean + /- SD of six replicate wells.
Control cpm were 4443 + /- 1336. 1% serum stimulated 236% + /- 44 of control.
The astensk indicates p < .001.
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Figure 10. IGF-II dose response in MC3T3-E1 cells. Values are expressed
as percentage of unstimulated control and are mean + /- SD of six replicate wells.
Control cpm were 1796 +/- 579. 1% serum stimulatea 321% + /- 75 of control. A
single asterisk indicates p <.l, while a double asterisk indicates p <.001.
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Figure 11. TGF-beta dose response in MC3T3-E1 cells. Values are
expressed as percentage of unstimulated control and are mean + /- SD of six
replicate wells and of four replicate wells for the control and other values,
respectively. Control cpm were 4413 + /-1420. A single asterisk indicates p <.02,
while a double asterisk indicates p < .01.
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Figure 12. Growth factor effects on cell proliferation in MC3T3-E1 cells.
Cell proliferation was measured by using the
thymidine incorporation assay.
Question marks indicate unidentified intracellular signalling pathways that mediate
the effects of the growth factors on proliferation.
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Figure 13. Time course of c-fos RNA induction by IGF-I in MC3T3-E1
cells. Subconfluent cultures were incubated for the indicated number of minutes
with IGF-I (10 ng/ml). 15 ug of total RNA was added to each lane and
electrophoresed through a 1.5% MOPS/formaldehyde agarose gel and transferred
to Nytran. The blot was hybridized with a mouse cDNA v-fos probe which detected
a 2.2 kb c-fos transcript. The lower panel shows results of methylene blue staining
of ribosomal RNA.
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Figure 14. Time course of c-fos RNA induction by IGF-II in MC3T3-E1
cells. Culture conditions, hybridization, and RNA loading were as described in
figure 13. 10 ng/ml of IGF-II was added for the indicated number of minutes, The
lower panel shows hybridization with chicken beta-actin.
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Figure 15. Time course of c-fos RNA induction by TGF-beta in MC3T3-E1
cells. Culture conditions, hybridization, and RNA loading were as described in
figure 13. 100 pg/ml of TGF-beta was added for the indicated number of minutes.
TTie lower panel shows results of methylene blue staining of ribosomal RNA.
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Figure 16. Time course of c-jun RNA by IGF-I in MC3T3-E1 cells.
Subconfluent cultures were incubated for the indicated number of minutes with
IGF-I (10 ng/ml). 15 ug of total RNA was added to each lane and electrophoresed
through a 1.5% MOPS/formaldehyde agarose gel and transferred to Nytran. The
blot was hybridized with a mouse cDNA c-jun probe which detected a 2.7 kb c-jun
transcript. The lower panel shows results of methylene blue staining of ribosomal
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Figure 17. Time course of c-jun RNA by IGF-II in MC3T3-E1 cells.
Culture conditions, hybridization, and RNA loading were as described in figure 16.
10 ng/ml of IGF-H was added for the indicated number of minutes. The lower
panel shows results of methylene blue staining of ribosomal RNA.
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Figure 18. Time course of c-jun RNA by TGF-beta in MC3T3-E1 cells.
Culture conditions, hybridization, and RNA loading were as described in figure 16.
100 pg/ml of TGF-beta was added for the indicated number of minutes. The lower
panel shows results of methylene blue staining of ribosomal RNA.
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Figure 19. Time course of jun-B RNA by IGF-I in MC3T3-E1 cells.
Subconfluent cultures were incubated for the indicated number of minutes with
IGF-I (10 ng/ml). 15 ug of total RNA was added to each lane and electrophoresed
through a 1.5% MOPS/formaldehyde agarose gel and transferred to Nytran. The
blot was hybridized with a mouse cDNA jun-B probe which detected a 2.1 kb jun-B
transcript. The lower panel shows results of methylene blue staining of ribosomal
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Figure 20. Time course of jun-B RNA by IGF-II in MC3T3-E1 cells.
Culture conditions, hybridization, and RNA loading were as described in figure 19.
10 ng/ml of IGF-H was added for the indicated number of minutes. The lower
panel shows results of methylene blue staining of ribosomal RNA.
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Figure 21. Time course of jun-B RNA by TGF-beta in MC3T3-E1 cells.
Culture conditions, hybridization, and RNA loading were as described in figure 19.
100 pg/ml of TGF-beta was added for the indicated number of minutes. Ine lower
panel shows results of methylene blue staining of ribosomal RNA
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Figure 22. Time course of jun-D RNA by IGF-I in MC3T3-E1 cells.
Subconfluent cultures were incubated for the indicated number of minutes with
IGF-I (10 ng/ml). 15 ug of total RNA was added to each lane and electrophoresed
through a 1.5% MOPS/formaldehyde agarose gel and transferred to Nytran. The
blot was hybridized with a mouse cDNA jun-D probe which detected a 1.8 kb jun-B
transcript. The lower panel shows results of methylene blue staining of ribosomal
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Figure 23. Time course of jun-D RNA by IGF-II in MC3T3-E1 cells.
Culture conditions, hybridization, and RNA loading were as described in figure 22.
10 ng/ml of IGF-II was added for the indicated number of minutes. The lower
panel shows results of methylene blue staining of ribosomal RNA
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Figure 24. Time course of jun-D RNA by TGF-beta in MC3T3-E1 cells.
Culture conditions, hybridization, and RNA loading were as described in figure 22.
100 pg/ml of TGF-beta was added for the indicated number of minutes. The lower
panel shows results of methylene blue staining of ribosomal RNA.
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Figure 25. Summary of Northern analyses in MC3T3-E1 cells. Values were
determined by laser densitometry and adjusted for actual loading as measured by
methylene blue staining.
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Figure 26. Potential molecular mechanism of growth factor action on cell
proliferation in MC3T3-E1 cells. In this model, IGF-I and IGF-II are proposed to
work through the proto-oncogene c-fos to increase cell proliferation. TGF-beta is
proposed to act through the proto-oncogenes c-fos and jun-B to decrease cell
proliferation.
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Figure 27. Potential mechanism for the regulation of IGFs by In-IGFBP
(MC-IGFBP-2). This model was originally designed for human bone cells to
account for the inhibition of IGF-II action [Mohan & Baylink, in press]. As
modified for the MC3T3-E1 cell system, either IGF-I or IGF-II could bind to InIGFBP and both the origin and target cells in this case would be MC3T3-E1 cells
which would allow the IGFs to act in an autocrine manner. The regulation of IGF
actions in this model occur at several steps including: 1) Secretion of IGFs, 2)
Secretion of In-IGFBP, 3) IGF receptor number and affinity and 4) Post receptor
events. IGF action may be prevented by binding to In-IGFBP, in which case IGFs
can not bind to their receptors.
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rv. DISCUSSION

A.

MC3T3-E1 CELL SYSTEM AND CULTURE CONDITIONS
MC3T3-E1 cells were chosen for this work since they are a permanent clonal

cell line which retains many properties of osteoblastic cells [Kodama et al, 1981].
Some osteoblast properties are synthesis of type I collagen and high alkaline
phosphatase activity which are stimulated by 1,25-dihydroxy vitamin D3 [Kurihara
et al., 1984], When MC3T3-E1 cells are in culture for prolonged times (longer than
14 day) they develop morphological characteristics of mature osteoblasts and
osteocytes and form calcified collagenous extracellular matrix resembling bone
[Sudo et al., 1983]. Since the cell line consists of a homogeneous population of
osteoblast-like cells, they make an ideal system in which to study the autocrine
effects of growth factors. This is in contrast to primary cultures which are com
posed of a mixture of cell types that produce a number of growth factors. These
growth factors can then in turn act on neighboring cells in a paracrine manner to
participate in number of unknown events which makes interpreting data in this
mixed cell culture system difficult.
The experiments involving MC3T3-E1 cells were carried out in serum-free
medium. MC3T3-E1 cells were maintained under these conditions for 10-14 days
without adverse effects. Procedures performed under serum-free conditions in
cluded collecting the conditioned medium, testing the effects of growth factors on
MC3T3-E1 cells in the cell proliferation assay and measuring the induction of
proto-oncogene transcripts by various growth factors. Serum-free conditions were
used to eliminate contamination with growth factors and other unknown factors
present in serum. To further reduce the influence of endogenous bone growth
regulators that might be secreted by MC3T3-E1 cells into the medium and thus
influence cell response, the serum-free medium was replaced one hour before
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adding growth factors in the cell proliferation assay and the mRNA induction
experiments.
B.

GROWTH FACTORS AND BINDING PROTEINS
The selection of growth factors to assay in the MC3T3-E1 cell CM was

based on the results from previous studies that show that IGF-I, IGF-II and TGFbeta are found in bone and are secreted by bone cells [Mohan et al., 1988a,b,c]. A
purification scheme (Fig. 1) was designed to separate these factors as well as to
purify a class of proteins made by bone cells called IGF BPs that bind to and regu
late the IGFs [Ooi & Herington, 1988; Baxter & Martin, 1989]. One of the limita
tions of the present work was the absence of data for other growth factors that are
also present in bone matrix and might be produced by MC3T3-E1 cells (e.g., FGF,
PDGF).
The CM, after partial concentration, was acidified with acetic acid to 1 M to
activate TGF-beta which is secreted by cells in a biologically inactive or latent form
[Pircher et al., 1986]. 1 M acetic acid also dissociates the IGFs from IGF BPs. The
concentrated CM was then applied to a Sephadex G-100 column to separate the
higher MW IGF BPs and TGF-beta from the lower MW IGFs. The Sephadex G100 column fractions were then tested for IGF and TGF-beta activity. Based on
the assay results, fractions were assigned into two different pools—a low MW pool
containing IGF-I (7649 daltons) and IGF-II (7470 daltons) and a high MW pool
containing TGF-beta (25 kDa) and the IGF BPs (25-50 kDa).
When the low MW G-100 pool containing the IGFs was applied to an IGFAb affinity column to further purify the IGFs, IGF-II bound to this column howev
er IGF-I did not. The antibodies used in this affinity column were made against
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human IGF-I in mice, and this could explain why mouse IGF-I did not bind to the
IGF-Ab affinity column. The high MW G-100 pool containing the IGF BPs and
TGF-beta was applied to an IGF affinity column to further purify the IGF BPs.
The bound fraction from the IGF affinity column was then subjected to HPLC RP
chromatography. This was done to separate the two binding proteins that had been
detected by N-terminal amino acid sequencing (Fig. 5) and Western ligand blotting
(Fig. 6) after the IGF affinity column step.
Two different assays, namely the IGF-II RRA and the BP assay, were used
to measure IGF BP levels produced by MC3T3-E1 cells. The IGF-II RRA, using
FI-35 cells, was originally developed to quantify IGF-II levels in samples [Mohan et
al., 1988c]. Later it was discovered that some IGF BPs present in the samples could
be detected in this assay by complexing with ^I-IGF-II and thus preventing -^IIGF-II from binding to the receptors. However, the ability of the IGF-II RRA to
detect all BPs was limited in that it should only recognize BPs that inhibit binding
of ^I-IGF-II to the receptors. In order to determine if additional BPs that are
not inhibitory were also present in the samples, a second assay called the BP assay
was used.
In contrast to the IGF-II RRA which only measured inhibitory IGF BPs, the
BP assay detected all of the BPs that complexed with the IGFs and were precipitat
ed by PEG. The limitation of this assay is that there may be small BPs which do
not precipitate with PEG. However, it is unlikely that these two assays missed any
BPs because Western ligand blotting detected only two different BPs present in
partially purified fractions of IGF BPs (Fig. 6). These two BPs were later purified
by HPLC RP chromatography and the MWs of these BPs corresponded to those of
CSF BP and the In-IGFBP.
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Three growth factors (Fig. 8) were found to be secreted by MC3T3-E1 cells
which had been previously described to be present in bones [Mohan et al.,
1988a,b,c]. These levels were obtained from affinity purified CM that was collected
every 48 hr. IGF-I was found to be the most abundant growth factor secreted, while
IGF-II was present in CM at l/10th that of IGF-I levels. MC3T3-E1 cell CM
contained TGF-beta levels of approximately twice that of IGF-II. Thus, IGF-I was
found at the greatest level in MC3T3-E1 cell CM followed by TGF-beta and then
IGF-II. It should be noted that these levels were lower than those found to be
effective on cell proliferation. The possible explanations for this include: 1) since
the relative levels of growth factors were determined after several steps of
purification, the percent recovery during these steps should be taken into
consideration when calculating the exact concentration of these growth factors in
the MC3T3-E1 CM. Thus, the real concentration of these growth factors may be an
order of magnitude higher than the estimated values. 2) Growth factors are not
diluted in a large amount of fluid in vivo as they are in culture dishes since cells are
normally present at a density which allows three dimensional contact and limits the
amount of fluid surrounding the cells.
These results are in agreement with rat studies that showed rat CM from 21
day old fetal calvarial cultures and rat monolayer cultures of parietal bone cells
contain much more IGF-I than IGF-II [Canalis et al., 1988c; McCarthy et al.,
1989c]. In contrast though, IGF-II has been found to be generally higher than IGFI in both sera and in skeletal extracts in many vertebrate classes [Bautista et al.,
1990; Mohan & Baylink, in press]. Mouse calvarial cultures have also been found
to secrete several-fold more IGF-II than IGF-I [Linkhart & Mohan, 1989].
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The results of this work show that IGF BPs can produce significant artifacts
in the IGF-IIRRA. For example, measurements of crude MC3T3-E1 cell CM
showed IGF-II levels to be about 1.5-fold higher than IGF-I levels. However, after
the IGFs and the IGF BPs had been separated from MC3T3-E1 cell CM, it became
clear that IGF-I was indeed the most prevalent IGF, and that most of the IGF-II
activity (> 90%) measured in the crude CM was in fact due to the presence of IGF
BP artifacts. In contrast to IGF-II, the IGF-I values obtained from crude MC3T3E1 cell CM corresponded well to the values obtained after purification of IGF-I.
Thus, the IGF BPs in the MC3T3-E1 cell CM produced less artifacts in the IGF-I
RIA as compared to the IGF-II RRA. These results suggest that the antibody
epitope in the RIA is different from the BP epitope. Therefore, caution should be
used when comparing the relative amounts of IGF-I and IGF-II in crude CM.
Another difficulty in interpreting the measurements of the various growth
factors was the fact that three different assays were employed to determine the
levels of IGF-I, IGF-II and TGF-beta, i.e. IGF-I was determined by RIA IGF-II by
RRA and TGF-beta by bioassay. Furthermore, these assays utilized non-mouse
standards (human IGF-I and IGF-II, bovine TGF-betal). Thus, these values may
only be relative and may not represent exact concentration.
The biological actions of IGF-I, IGF-II and TGF-beta were also determined
on MC3T3-E1 cells. IGF-I and IGF-II (Figs. 9 & 10) were found to stimulate cell
proliferation, while TGF-beta was found to inhibit cell proliferation. The actions of
both IGFs on MC3T3-E1 cells are in agreement with other studies using chick,
mouse and human bone cells in serum-free cultures that show IGF-I and IGF-II
stimulate cell proliferation in a dose dependent manner [Mohan et al., 1986;
Kasperk et al., in press; Wergedal et al., 1990].
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In contrast to the IGFs, the actions of TGF-beta as reviewed in the introduc
tion are complex. TGF-beta can either stimulate or inhibit cell proliferation and
increase or decrease bone differentiation markers depending on the cell types
studied and culture conditions used. In addition, there are at least four different
members of the TGF-beta family whose interaction with at least three different
types of TGF-beta receptors are currently being investigated. This underscores the
fact that the biological action of TGF-beta is highly complex.
In this work, TGF-beta was found to decrease cell proliferation in a dose
dependent manner in MC3T3-E1 cells as measured by

thymidine incorporation.

In addition, time course studies by Uneno et al., [1989] indicate that TGF-beta has
a biphasic effect on cell proliferation as measured by

thymidine incorporation.

These studies show that TGF-beta decreases cell proliferation acutely, but upon
exposures of greater than 48 hr, cell proliferation is increased. The findings in this
work agree with those of Uneno et al., since MC3T3-E1 cells were incubated with
TGF-beta for only 18 hr. In contrast to these findings, TGF-beta increases cell
proliferation in primary cultures of mouse calvarial cells [Kasperk et al., in press].
The effects of TGF-beta on collagen synthesis and alkaline phosphatase
activity have also been determined in MC3T3-E1 cells [Ibbotson et al., 1989]. Both
low and high doses of TGF-beta increase collagen synthesis in serum-free condi
tions. TGF-beta has a biphasic effect on alkaline phosphatase activity with TGFbeta inhibiting activity at high doses but stimulating at low doses. In the presence
of serum, TGF-beta has similar effects in MC3T3-E1 cells except that high doses of
TGF-beta decrease collagen synthesis. Thus, the actions of TGF-beta are very
complex even in a clonal osteoblast-like cell line such as the MC3T3-E1 cell line.
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Since MC3T3-E1 cells produce and respond to IGF-I, IGF-II and TGF-beta,
these factors act in an autocrine manner to influence MC3T3-E1 cell proliferation.
In addition, these factors can also regulate themselves. Recent studies in MC3T3E1 cells show that IGF-II increases both message levels and protein secretion of
IGF-I. In contrast, TGF-beta decreases protein secretion of IGF-I, while IGF-I
message levels are unchanged [Tremollieres et al., in press a]. The effects of IGFII and TGF-beta on IGF-I protein secretion are also cell density dependent. IGF-I
secretion exhibits the highest sensitivity to IGF-I and TGF-beta at low MC3T3-E1
cell density and the lowest sensitivity at high MC3T3-E1 cell density [Tremollieres
et al., in press b]. This shows that MC3T3-E1 cells are most responsive to growth
factors when they have the most opportunity to proliferate. That factors made by
MC3T3-E1 cells should in turn have effects on other growth factors made by
MC3T3-E1 cells is not surprising, especially in view of the fact that MC3T3-E1 cells
can be maintained in serum-free conditions for long periods of time.
Based on the data presented in this study and on the findings from other
investigators in our lab [Tremollieres et al., in press a,b], it can be proposed that
the proliferation of MC3T3-E1 cells is regulated by local factors. Thus it is possible
that when MC3T3-E1 cells need to propagate, they could secrete IGF-I. In con
trast, when a sufficient number of cells were attained, TGF-beta could be secreted
which would inhibit cell proliferation.
MC3T3-E1 cells in culture also produce two different binding proteins based
on N-terminal amino acid sequence analysis (Fig. 5) and Western ligand blotting
(Fig. 6). This data showed that MC3T3-E1 cell CM contained a binding protein
with sequence identity to CSF BP (MC-IGFBP-1) [Roghani et al., 1989] and anoth
er binding protein with sequence identity with In-IGFBP (MC-IGFBP-2) [Mohan et

127
al., 1989c]. MC3T3-E1 cells are the first bone cells shown to make a BP which has
sequence identity with CSF BP (MC-IGFBP-1). In addition, based on the relative
yields of amino acid recovery from N-terminal sequence analysis data, the MCIGFBP-1 appears to be about 3 times as abundant as MC-IGFBP-2 in MC3T3-E1
cell CM. However, the fact that MC-IGFBP-1 appears to be more abundant does
not mean that it is physiologically more important since the affinity of these two
BPs towards the IGFs and the relative potency of these BPs in modulating the
actions of IGFs must be considered.
Like the growth factors made by MC3T3-E1 cells, these BPs also could play
an important autocrine role in regulating MC3T3-E1 cells. This is supported by the
finding that exogenous addition of In-IGFBP purified from TE-89 human osteosar
coma cell CM inhibits basal cell proliferation by about 40% of control [Mohan et
al., 1989c]. In this work, attempts were also made to study the biological actions of
the two BPs purified from MC3T3-E1 cell CM on MC3T3-E1 cells. Since adequate
amounts of purified BP were not available at this time, these attempts proved to be
unsuccessful in giving conclusive evidence. However, based on studies with other
purified IGF BPs it can be concluded that the regulation of the IGFs in MC3T3-E1
cells is rather complex.
Another interesting finding in this study is that although MC3T3-E1 cells
produce 10-fold more IGF-I than IGF-II, the major IGF BP produced by these cells
has a 10-fold higher affinity for IGF-II than IGF-I [Roghani et al., 1989]. It is not
know whether this finding has any physiological significance. In this regard, one
could propose that a cell type that produces mostly IGF-I may produce a BP with
selective affinity for IGF-II. This BP could then act on neighboring cells that
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produce IGF-II in a paracrine manner without having an autocrine effect.
Fig. 26 shows a model of how MC-IGFBP-2 (In-IGFBP) might possibly
regulate IGF-II actions. This model was originally developed for human bone cells
where IGF-II is the primary mitogen [Mohan & Baylink, in press]. The actions of
the IGFs in the local environment depend not only on the concentration of the
IGFs but also on the concentration of MC-IGFBP-2. Since MC3T3-E1 cells make
IGF-I, IGF-II and MC-IGFBP-2, this model is also applicable to MC3T3-E1 cells.
In the absence of MC-IGFBP-2, IGF-I or IGF-II would be able to stimulate cell
proliferation. However, if MC-IGFBP-2 were present, it could complex with the
IGFs and prevent them from binding to the IGF receptors. Thus, the effect of the
IGFs would be abolished.
C.

MOLECULAR STUDIES-FOS AND JUN
This is the first study examining the role of the bone growth factors IGF-I,

IGF-II and TGF-beta on the expression of c-fos and jun family members in bone
cells and the role of IGF-II on fos and jun expression in any cell type. The levels of
c-fos induction observed in MC3T3-E1 osteoblast cultures followed rapid and tran
sient kinetics similar to that seen in other studies in which FCS, PDGF, FGF or
EGF were used to induce c-fos expression [Mueller et al., 1984c]. An earlier report
concluding that osteoblastic cells express relatively low levels of c-fos may have
been based on the differences in culture conditions as well as analysis of cells that
were not adequately induced with mitogens [Mueller et al., 1984a].
Before the commercially obtained Oncor v-fos probe was used, attempts in
earlier studies to hybridize filters with a human c-fos probe (plZn, gift from I.
Verma) were unsuccessful. This might have been caused by cross-species
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hybridization problems. Alternatively, this could have been due to the low amount
of c-fos message present in the RNA preparations. Consistent with this idea, NIH3T3 cells after induction with PDGF have c-fos levels that only constitute 0.0001%
of total RNA (.005% of mRNA) or 5-10 copies per cell [Verma et al., 1985].
Previous studies have shown that IGF-I stimulates c-fos expression in several
cell types. For example, IGF-I induces c-fos mRNA in rat skeletal muscle cells and
in FRTL5 rat thyroid cells [Ong et al., 1987; Damante et al., 1988]. Taken together
these studies provide evidence that c-fos induction may be a component of the
molecular mechanisms underlying the actions of the IGFs.
Since both IGFs are present in relatively high abundance in the bone matrix,
are produced by bone cells and act on bone cells [Raisz, 1988; Mohan et al.,
1988a,b] it has been suggested that they play an important role in the regulation of
osteoblast proliferation and differentiation. In support of a role of c-fos in osteo
blast proliferation, both IGFs were found to stimulate MC3T3-E1 cell proliferation
as measured by an increase in DNA synthesis (Figs. 9 & 10) and in cell numbers at
concentration equivalent to those that induced c-fos expression (unpublished data).
This increase in cell proliferation was measured 18-48 hr after the addition of the
IGFs. The earlier transient increase in c-fos mRNA suggests that c-fos expression
is necessary for cell proliferation. Evidence supporting this hypothesis (in other cell
types) includes a study in which fos anti-sense RNA blocked PDGF induced mouse
cell proliferation [Nishikura et al., 1987]. It should also be noted that c-fos protein,
in addition to c-fos mRNA, is rapidly induced (1-2 hr after serum stimulation) and
thus would be available to increase cell proliferation.
Since TGF-beta and the IGFs had opposing effects on cell proliferation, it
was initially proposed that the IGFs might induce c-fos gene expression, while
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TGF-beta might inhibit basal c-fos expression. Northern analyses of c-fos transcript
levels induced by IGF and TGF-beta (summarized in Fig. 25) indicate that the time
courses of c-fos induction by the IGFs were similar with a maximum induction at 15
and 30 min. Interestingly, c-fos mRNA was also induced by TGF-beta, though the
time course was slightly different. In contrast to the IGFs, TGF-beta induced c-fos
transcripts maximally at 30 and 60 min. It is possible that the delay in c-fos induc
tion observed with TGF-beta could account for the opposite effects observed on
cell proliferation as compared to the IGFs. However, there is probably a different
signalling mechanism other than fos involved that is responsible for the differential
effects on cell proliferation.
As it became obvious that fos proteins form heterodimers with jun proteins
that allow fos to bind to DNA in the nucleus [Sassone-Corsi et al., 1988a], studies
were initiated to investigate the expression of jun transcripts to determine if a dif
ference in jun expression might correlate with the differences in cell proliferation
observed with the IGFs and TGF-beta. It was known that c-jun is induced by
serum, FGF and PDGF in mouse 3T3 fibroblast cells [Ryder & Nathans, 1988b],
and that uninduced cells produce low levels of c-jun transcripts [Lamph et al.,
1988]. Even less was known about the expression of the two newer members of the
jun family, jun-B and jun-D. In mouse 3T3 fibroblast cells, jun-B transcripts are
induced more by serum, PDGF and FGF than c-jun transcripts [Ryder & Nathans,
1988b], while jun-D mRNA is present at higher levels than c-jun mRNA and is also
induced less by serum [Ryder et al., 1989].
In this work, MC3T3-E1 cells were shown to express detectable levels of cjun mRNA transcripts that could only be induced by IGF-II and not by IGF-I or
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TGF-beta (Fig. 25). A similar pattern of expression was also observed for jun-D
transcripts. This may explain in part how transgenic mice transfected with the c-fos
gene form lesions of increased bone formation [Ruether et al., 1987], since signifi
cant levels of jun might be expressed in bone cells but not in other cell types. This
could allow the complexing of fos-jun heterodimers that would facilitate the forma
tion of bone lesions by changing bone cell gene expression.
The expression of jun-B transcripts in MC3T3-E1 cells was found to be
completely different from that of c-jun and jun-D transcripts (Fig. 25). jun-B tran
scripts were undetectable when either IGF-I or IGF-II were added, but the tran
scripts were induced by TGF-beta. The induction of jun-B transcripts by TGF-beta
might be part of the molecular mechanism by which TGF-beta decreases cell pro
liferation (Fig. 26). It is possible that a jun-B/fos heterodimer could form an intra
cellular switch that could stop cell proliferation and/or induce cell differentiation.
One question which arises from the results of this work is what membrane
receptors are involved in mediating the effects of IGF-I and IGF-II on fos and jun
expression. One possibility might be that IGF-II is acting through the type I IGF
receptor as has been previously shown in human skin fibroblasts [Conover et al.,
1986]. Alternately, IGF-I and IGF-II might induce fos and jun by acting through
separate and distinct receptors. Recent studies in primary mouse and chick calvaria
cultures using specific IGF type II inhibitory antibodies suggest that the mitogenic
activity of IGF-II is mediated at least in part by the type II IGF receptor in bone
cells [Mohan et al., 1989a]. The findings in this study that IGF-II but not IGF-I
induce expression of c-jun further support the idea that IGF-I and II mediate their
actions by different mechanisms.
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D.

FUTURE STUDIES

1)

The first study to do would be to clone the gene for the MC-IGFBP-1. Since

the first 15 amino acids are known, oligonucleotide probes could be made based on
this sequence information. These oligos could then be used to find clones in a
cDNA library made from MC3T3-E1 cells. These clones could then be sequenced
and the complete amino acid sequence of the MC-IGFBP-1 could then be derived.
2)

The regulation of MC-IGFBP-1 could be studied with the MC-IGFBP-1

oligonucleotide probe. Since a probe for In-IGFBP is already available and has
been shown to cross hybridize to the MC3T3-E1 cell MC-IGFBP-2, the regulation
of both of these BPs could be compared to see if MC-IGFBP-1 and MC-IGFBP-2
are independently, or coordinate^ regulated. Since it is already known that cAMP
increases In-IGFBP in TE-85 cells, cAMP could be the first potential regulator to
be studied in MC3T3-E1 cells. In addition, the effects of IGF-I, IGF-II and TGFbeta on BP transcript level could also be investigated. This could provide signifi
cant information on the regulation of the production of these two BPs in MC3T3E1 cells.
3)

A third study to pursue would be to look at the effect on cell proliferation of

shutting down c-fos and jun gene expression by transfected antisense RNA. Earlier
efforts to determine the role of c-fos by inhibiting its expression using antisense
RNA gave confusing and ambiguous results. Since clones of MC3T3-E1 cells that
have been transfected with fos sense and antisense genes are already available, this
line of research could be easily accomplished. Transfected cells were selected on
the basis of resistance to the antibiotic G418. However it should be determined
first if these clones can actually express the transfected genes when stimulated by
dexamethasone before further studies are performed. This could be done by
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measuring the expression of beta-globin that is also present in these constructs. It
may also be necessary to stimulate transcription from the MMTV promoter with
other steroid hormones (androgen or estrogen) to eliminate the effects of
dexamethasone which inhibits cell proliferation.
4)

Another important area to study would be the biological actions of MC-

IGFBP-1 and MC-IGFBP-2 on MC3T3-E1 cells. In order to do this CM (at least 5
L) would need to be collected and the binding proteins purified as before. As
already discussed, past efforts at determining BP action on MC3T3-E1 cell prolif
eration were not successful most likely due to the limited amount of sample avail
able. Another related experiment to be done would be to measure the affinity of
each BP for IGF-I and IGF-II. This could be accomplished in a competitive-bind
ing experiment where different amounts of either IGF-I or IGF-II would compete
for binding of 125I-IGF-I or 125I-IGF-II to each BP.
5)

Since there are many members in the TGF-beta family (four different forms

have been cloned), one area of study could be to determine the exact forms and
amounts of TGF-beta that are made by MC3T3-E1 cells. In addition, the effects of
TGF-beta3 (recombinant form is available) and TGF-beta4 (has not been purified
yet) on MC3T3-E1 cells could be measured in view of the fact the TGF-betal and
TGF-beta2 are known to be equipotent in bone cells but have different potency in
some other cell types.
6)

The results of some of the Northern analyses would be more informative if

additional time points were added to some of the oncogenes. In particular it would
be useful to know if TGF-beta could induce fos mRNA at 15 min as do the IGFs.
In addition, the time course of jun-B induction by TGF-beta should be extended
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past 4 hr to determine when jun-B levels return to uninduced levels.
E.

SUMMARY
In summary, MC3T3-E1 cells produce a variety of bone regulators, namely

IGF-I, TGF-beta and IGF-II in descending order of abundance. MC3T3-E1 cells
also produce two IGF binding proteins-MC-IGFBP-1 and MC-IGFBP-2. The
major BP, MC-IGFBP-1, has sequence identity with CSF BP, while the minor BP,
MC-IGFBP-2, has sequence identity with In-IGFBP. This is the first time that an
IGF BP with selective affinity for IGF-II has been shown to be produced by bone
cells. In addition, the growth factors made by MC3T3-E1 cells act on MC3T3-E1
cells in an autocrine manner. IGF-I and IGF-II increase cell proliferation while
TGF-beta decreases cell proliferation as measured by

thymidine incorporation.

IGF-I and IGF-II cause a rapid and transient induction of c-fos in MC3T3-E1 cells
similar to that observed with other growth factors in other cell types. TGF-beta
causes a similar rapid induction of c-fos which is slightly delayed, c-jun and jun-D
transcripts are constitutively expressed in the presence of IGF-I and TGF-beta.
However, IGF-II can induce both types of transcripts. jun-B transcripts are unde
tectable with IGF-I and IGF-II, but TGF-beta rapidly and dramatically induces junB in MC3T3-E1 cells. The differences in the c-fos and jun-B expression may be a
component in the molecular mechanism controlling cell proliferation in MC3T3-E1
cells.
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